WO2021170109A1 - Tropomyosin receptor kinase (trk) degradation compounds and methods of use - Google Patents

Tropomyosin receptor kinase (trk) degradation compounds and methods of use Download PDF

Info

Publication number
WO2021170109A1
WO2021170109A1 PCT/CN2021/078240 CN2021078240W WO2021170109A1 WO 2021170109 A1 WO2021170109 A1 WO 2021170109A1 CN 2021078240 W CN2021078240 W CN 2021078240W WO 2021170109 A1 WO2021170109 A1 WO 2021170109A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
carbocyclyl
membered
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/078240
Other languages
English (en)
French (fr)
Inventor
Jing Liu
Michael Bruno Plewe
Jialiang Wang
Xiaoran HAN
Liqun Chen
Chengwei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cullgen Shanghai Inc
Original Assignee
Cullgen Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullgen Shanghai Inc filed Critical Cullgen Shanghai Inc
Priority to MX2022010465A priority Critical patent/MX2022010465A/es
Priority to AU2021225981A priority patent/AU2021225981A1/en
Priority to US17/904,822 priority patent/US12410171B2/en
Priority to EP21760113.7A priority patent/EP4110772A4/en
Priority to CN202510191023.3A priority patent/CN120058711A/zh
Priority to CN202180031506.7A priority patent/CN115697989B/zh
Priority to JP2022551553A priority patent/JP7692924B2/ja
Priority to IL295799A priority patent/IL295799A/en
Priority to CA3173262A priority patent/CA3173262A1/en
Priority to KR1020227033274A priority patent/KR20230010070A/ko
Priority to BR112022016901A priority patent/BR112022016901A2/pt
Publication of WO2021170109A1 publication Critical patent/WO2021170109A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • bivalent compounds e.g., bi-functional small molecule compounds
  • compositions comprising one or more of the bivalent compounds
  • methods of use of the bivalent compounds for the treatment of certain diseases in a subject in need thereof The disclosure also relates to methods for identifying such bivalent compounds.
  • X 1 and X 2 are independently selected from CH and N;
  • X 3 and X 4 are independently selected from C (O) and CR 4 R 5 ;
  • R 1 is selected from H, -NR 2 R 3 , halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy;
  • R 2 , R 3 , R 4 , and R 5 are independently selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy; and
  • L is selected from a bond
  • one of X 3 and X 4 is C (O) and the other is CR 4 R 5 ;
  • X 1 and X 2 are each N.
  • X 3 is C (O) and X 4 is CR 4 R 5 . In some embodiments, X 3 is C (O) and X 4 is CR 4 R 5 .
  • X 3 and X 4 are both C (O) . In some embodiments, X 3 and X 4 are both CR 4 R 5 .
  • R 1 is -NR 2 R 3 . In some embodiments, R 1 is
  • X 1 and X 2 are independently selected from CH and N;
  • X 3 and X 4 are independently selected from C (O) , CR 4 R 5 , and NR 6 ;
  • R 1 is selected from H, -NR 2 R 3 , halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted aryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy;
  • R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 7 ) R”, R’C (S) N (R 7 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 7 ) R”, R’N (R 7 ) R”, R”N (R 7 ) COR”, R’N (R 7 ) CON (R 8 ) R”, R’N (R 7 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 3 or X 4 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 7 and R 8 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • L is selected from
  • X 1 and X 2 are each N.
  • At least one of X 3 and X 4 is NR 6 . In some embodiments, X 3 and X 4 are both NR 6 .
  • either X 3 or X 4 is -N- (2, 6-dioxopiperidin-3-yl) .
  • R 1 is -NR 2 R 3 . In some embodiments, R 1 is
  • L is connected to X 3 . In some embodiments, L is connected to X 4 .
  • X 1 and X 2 are independently selected from CH and N;
  • one of X 3 and X 4 is C (O) and the other is CR 1 R 2 ;
  • X 3 and X 4 are each C (O) ;
  • R 1 and R 2 are independently selected from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy.
  • X 1 and X 2 are each N.
  • X 1 and X 3 are independently selected from CR 1 , CR 1 R 2 , O, N, and NR 1 ;
  • X 2 is selected from N, CO, and CH;
  • Y is selected from O, NR 8 and CR 8 R 9 ;
  • Ar is selected from C 6-10 aryl and 5-to 10-membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from hydrogen, halogen, CN, NO 2 , OR 17 , SR 17 , NR 18 R 19 , COR 17 , CO 2 R 17 , CONR 18 R 19 , SOR 17 , SO 2 R 17 , SO 2 NR 18 R 19 , NR 17 COR 19 , NR 17 C (O) NR 18 R 19 , NR 18 SOR 17 , NR 18 SO 2 R 17 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 1-8 alkyl amino, optionally substituted C 3-10 carbocyclyl, -O-
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 21 ) R”, R’C (S) N (R 21 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 21 ) R”, R’N (R 21 ) R”, R”N (R 21 ) COR”, R’N (R 21 ) CON (R 22 ) R”, R’N (R 21 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 1 or X 3 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 1 and R 2 are independently selected at each occurrence from H, halogen, optionally substituted C 1- 6 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1- 6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • R 3 is selected from a bond, -OR 14 -, -SR 14 -, -N (R 15 ) R 14 -, -COR 14 -, -CO 2 R 14 -, -CON (R 15 ) R 14 -, -SOR 14 -, -SO 2 R 14 -, -SO 2 N (R 15 ) R 14 -, -N (R 16 ) COR 14 -, -N (R 16 ) CON (R 15 ) R 14 -, N (R 16 ) SOR 14 -, -N (R 16 ) SO 2 R 14 -, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl
  • R 4 , R 5 , and R 6 are independently selected from hydrogen, halogen, CN, NO 2 , OR 10 , SR 11 , NR 12 R 13 , COR 10 , CO 2 R 10 , C (O) NR 12 R 13 , SOR 10 , SO 2 R 10 , SO 2 NR 12 R 13 , NR 10 C (O) R 13 , NR 10 C (O) NR 12 R 13 , NR 10 SOR 13 , NR 10 SO 2 R 13 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1- 8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, and optionally substituted 3-to 10-membered heterocyclyl;
  • R 7 is selected from optionally substituted C 1-8 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 8 and R 9 are independently selected from hydrogen, halogen, OH, optionally substituted C 1-8 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , and optionally substituted 3-to 10-membered heterocyclyl; or
  • R 8 and R 9 are taken together with the atom to which they are connected to form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 10 , R 11 , R 12 , and R 13 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 12 and R 13 are taken together with the atom to which they are connected to form an optionally substituted 3-to 10-membered heterocyclyl;
  • R 14 is selected from null, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 15 and R 16 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 14 and R 15 together with the atom to which they are connected, optionally form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 17 , R 18 , and R 19 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 18 and R 19 are together with the atom to which they are connected to form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 21 and R 22 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring.
  • L is selected from
  • R 4 , R 5 , and R 6 are each hydrogen.
  • Y is CR 8 R 9 . In some embodiments, Y is CH 2 .
  • R 7 is optionally substituted C 6-10 aryl. In some embodiments, R 7 is
  • Ar is C 6-10 aryl substituted with NR 18 R 19 . In some embodiments, Ar is
  • R 3 is optionally substituted 3-to 10-membered heterocyclyl. In some embodiments, R 3 is
  • X 1 is CR 1 , X 2 is CH, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is CR 1 .
  • X 1 is CR 1 , X 2 is N, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is N, and X 3 is CR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is N.
  • X 1 is N, X 2 is CH, and X 3 is NR 1 .
  • X 1 is CR 1 R 2 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is O, X 2 is CO, and X 3 is NR 1 .
  • X 1 is CR 1 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is N, X 2 is CO, and X 3 is NR 1 .
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • X 1 and X 3 are independently selected from CR 1 , N, and NR 1 ;
  • X 2 is selected from N and CH;
  • Y 1 is selected from N and CR 6 ;
  • Y 2 , Y 3 , and Y 4 are independently selected from N and C, with the proviso that only one of Y 2 , Y 3 , and Y 4 is N;
  • Z is selected from null, a bond, C (R 5 ) 2 , C (R 5 ) 2 C (R 5 ) 2 , CO, C (R 5 ) 2 CO, CONR 5 , C (R 5 ) 2 O, C (R 5 ) 2 NR 5 and CH 2 NR 5 ;
  • Ar 1 and Ar 2 are independently selected from C 6-10 aryl and 5-to 10-membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 10 , SR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2-8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 haloalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optional
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 13 ) R”, R’C (S) N (R 13 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 13 ) R”, R’N (R 13 ) R”, R”N (R 13 ) COR”, R’N (R 13 ) CON (R 14 ) R”, R’N (R 13 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 1 or X 3 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 1 is selected at each occurrence from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • R 3 is selected from a bond, -OR 7 -, -SR 7 -, -N (R 8 ) R 7 -, -COR 7 -, -CO 2 R 7 -, -CON (R 8 ) R 7 -, -SOR 7 -, -SO 2 R 7 -, -SO 2 N (R 8 ) R 7 -, -N (R 9 ) COR 7 -, -N (R 9 ) CON (R 8 ) R 7 -, N (R 9 ) SOR 7 -, -N (R 9 ) SO 2 R 7 -, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl
  • R 4 and R 5 are independently selected at each occurrence from hydrogen, halogen, OH, NH 2 , CN, NO 2 , optionally substituted C 1-4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1- 4 alkoxy, optionally substituted C 1-4 heteroalkyl, optionally substituted C 1-4 haloalkyl, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , -NH- (optionally substituted C 3-10 carbocyclyl) , and optionally substituted 3-to 10-membered heterocyclyl;
  • R 6 is selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, and optionally substituted 3-to 10-membered heterocyclyl;
  • R 7 is selected from null, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 8 and R 9 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 7 and R 8 together with the atom to which they are connected, optionally form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 10 , R 11 , and R 12 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2- 8 alkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 11 and R 12 are together with the atom to which they are connected to form an optionally substituted C 3 -C 10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 13 and R 14 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • n 0, 1, 2, 3, or 4.
  • L is selected from
  • Y 1 is N
  • Y 2 is N
  • Y 3 is C
  • Y 4 is C
  • Ar 1 is C 6-10 aryl optionally substituted with halogen. In some embodiments, Ar 1 is
  • Ar 2 is C 6-10 aryl optionally substituted with NR 11 R 12 . In some embodiments, Ar 2 is
  • R 3 is optionally substituted 3-to 10-membered heterocyclyl. In some embodiments, R 3 is
  • R 4 is hydrogen
  • Z is C (R 5 ) 2 . In some embodiments, Z is CH 2 .
  • n 0.
  • X 1 is CR 1 , X 2 is CH, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is CR 1 .
  • X 1 is CR 1 , X 2 is N, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is N, and X 3 is CR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is N.
  • X 1 is N, X 2 is CH, and X 3 is NR 1 .
  • R 1 is methyl. In some embodiments, R 1 is
  • a bivalent compound disclosed herein comprises a tropomyosin receptor kinase (TRK) ligand conjugated to a degradation tag, or a pharmaceutically acceptable salt or analog thereof.
  • TRK tropomyosin receptor kinase
  • the TRK ligand is capable of binding to a TRK protein comprising a TRK, a TRK mutant, a TRK deletion, a TRK splicing or a TRK fusion protein.
  • the TRK ligand is a TRK kinase inhibitor or a portion of TRK kinase inhibitor.
  • the TRK ligand is selected from the group consisting of entrectinib (RXDX-101) , GNF-8625, larotrectinib (LOXO-101; ARRY-470) , altiratinib (DCC2701, DCC-270, DP-5164) , sitravatinib (MGCD516) , cabozantinib (XL-184, BMS-907351) , dovitinib (TKI-258, CHIR-258) , milciclib (PHA-848125AC) , belizatinib (TSR-011) , GZ389988, pegcantratinib, AZD7451, TPX-0005, LOXO-195, regorafenib, DS-6051b, F17752, PLX7486, AZD-6918, ASP7962, ONO-4474, PF-06273340, and analogs thereof.
  • RXDX-101 entrec
  • the degradation tag binds to an ubiquitin ligase, or is a hydrophobic group or a tag that leads to misfolding of the TRK protein.
  • the ubiquitin ligase is an E3 ligase.
  • the E3 ligase is selected from the group consisting of a cereblon E3 ligase, a VHL E3 ligase, an IAP ligase, a MDM2 ligase, a TRIM24 ligase, a TRIM21 ligase, a KEAP1 ligase, DCAF16 ligase, RNF4 ligase, RNF114 ligase, and AhR ligase.
  • the degradation tag is selected from the group consisting of pomalidomide, thalidomide, lenalidomide, VHL-1, adamantane, 1- ( (4, 4, 5, 5, 5-pentafluoropentyl) sulfinyl) nonane, nutlin-3a, RG7112, RG7338, AMG232, AA-115, bestatin, MV-1, LCL161, CPD36, GDC-0152, CRBN-1, CRBN-2, CRBN-3, CRBN-4, CRBN-5, CRBN-6, CRBN-7, CRBN-8, CRBN-9, CRBN-10, CRBN-11, and analogs thereof.
  • the TRK ligand is conjugated to the degradation tag via a linker moiety.
  • the TRK ligand comprises a moiety of Formula 1
  • X is selected from CR’R”, CO, O, S, SO, SO 2 , and NR’, wherein
  • R’ and R are independently selected from hydrogen, halogen, OH, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, and optionally substituted 3-10 membered heterocyclyl; or
  • R’ and R” together with the atom to which they are connected optionally form an optionally substituted 3-8 membered carbocyclyl or heterocyclyl ring;
  • R is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 1 , R 2 , and R 3 are independently selected from hydrogen, halogen, CN, NO 2 , OR 5 , SR 6 , NR 7 R 8 , COR 5 , CO 2 R 5 , C (O) NR 7 R 8 , SOR 5 , SO 2 R 5 , SO 2 NR 7 R 8 , NR 7 C (O) R 8 , NR 5 C (O) NR 7 R 8 , NR 7 SOR 8 , NR 7 SO 2 R 8 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, optionally
  • R 5 , R 6 , R 7 , and R 8 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, or optionally substituted heteroaryl, or
  • R 7 and R 8 together with the atom to which they are connected optionally form an optionally substituted 3-8 membered heterocyclyl ring;
  • R 4 is connected to the linker moiety of the bivalent compound, and is selected from a bond, -OR 9 -, -SR 9 -, -NR 10 R 11 -, -COR 9 -, -CO 2 R 9 -, -CONR 10 R 11 -, -SOR 9 -, -SO 2 R 9 -, -SO 2 NR 10 R 11 -, -NR 10 COR 11 -, -NR 9 CONR 10 R 11 -, -NR 10 SOR 11 -, -NR 10 SO 2 R 11 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alky
  • R 9 , R 10 , and R 11 are independently selected from null, a bond, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-,
  • R 10 and R 11 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • Ar is selected from aryl and heteroaryl group, each of which is optionally substituted with one or more substituents independently selected from hydrogen, halogen, CN, NO 2 , OR 12 , SR 12 , NR 13 R 14 , COR 12 , CO 2 R 12 , CONR 13 R 14 , SOR 12 , SO 2 R 12 , SO 2 NR 13 R 14 , NR 13 COR 14 , NR 15 C (O) NR 13 R 14 , NR 13 SOR 14 , NR 13 SO 2 R 14 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8
  • R 12 , R 13 , R 14 , and R 15 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 13 and R 14 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • X is selected from CR’R”, O, and NR’; wherein
  • R’ and R are independently selected from hydrogen, F, OH, optionally substituted C1-C3 alkyl, and optionally substituted C1-C3 alkoxy; or
  • R’ and R” together with the atom to which they are connected optionally form an optionally substituted 3-6 membered carbocyclyl or heterocyclyl ring.
  • X is selected from CH 2 , cyclopropylene, CHF, CF 2 , O, NH, NCH 3 , NCH 2 CH 3 , and N-isopropyl.
  • R is selected from optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • R is selected from optionally substituted phenyl and optionally substituted heteroaryl.
  • X is CH 2 ; and R is 3, 5-difluorophenyl.
  • R 1 , R 2 , and R 3 are independently selected from hydrogen, F, Cl, and OH.
  • R 4 -Ar is selected from a moiety of formulae A1, A2, A3, and A4:
  • R a is selected from hydrogen, halogen, CN, NO 2 , OR 12 , SR 12 , NR 13 R 14 , COR 12 , CO 2 R 12 , CONR 13 R 14 , SOR 12 , SO 2 R 12 , SO 2 NR 13 R 14 , NR 15 COR 14 , NR 15 C (O) NR 13 R 14 , NR 15 SOR 14 , NR 15 SO 2 R 14 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted
  • R 12 , R 13 , R 14 , and R 15 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, aryl, and optionally substituted heteroaryl, or
  • R 13 and R 14 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R 4 -Ar is selected from a moiety of formulae A1, A3, A3, and A4:
  • R a is selected from hydrogen, halogen, NR 13 R 14 , and NR 13 COR 14 , wherein
  • R 13 and R 14 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, phenyl, and optionally substituted C 5 -C 6 heteroaryl, or
  • R 13 and R 14 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R a is selected from H, (tetrahydro-2H-pyran-4-yl) amino, and 2-fluoroethylamino.
  • R 4 is selected from optionally substituted
  • the TRK ligand comprises a moiety of Formula 2:
  • X 1 , X 2 , X 3 , and X 4 are independently selected from C, CR’, and N (preferly, X 1 is selected from CR’ and N; and X 2 , X 3 , and X 4 are independently selected from C and N) , wherein
  • R’ is selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 3 -C 6 carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • X is selected from null, a bond, C (R 2 ) 2 , C (R 2 ) 2 C (R 2 ) 2 , CO, C (R 2 ) 2 CO, CONR 2 , C (R 2 ) 2 O, C (R 2 ) 2 NR 2 and CH 2 NR 2 ;
  • R 1 and R 2 are independently selected from hydrogen, halogen, OH, NH 2 , CN, NO 2 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 alkoxyalkyl, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 1 -C 4 hydroxyalkyl, optionally substituted C 1 -C 4 alkylaminoC 1 -C 4 alkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl;
  • n 1 to 4.
  • R 3 is connected to the linker moiety of the bivalent compound either directly or through R 4 ;
  • R 3 and R 4 are independently selected from null, a bond, -OR 5 -, -SR 5 -, -NR 6 R 7 -, -COR 5 -, -CO 2 R 5 -, -CONR 6 R 7 -, -SOR 5 -, -SO 2 R 5 -, -SO 2 NR 6 R 7 -, -NR 6 COR 7 -, -NR 5 C (O) NR 6 R 7 -, -NR 6 SOR 7 -, -NR 6 SO 2 R 7 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alky
  • R 5 , R 6 and R 7 are independently selected from null, a bond, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-alkylene, optionally substituted C 1 -C 8 alkylene
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • Ar 1 and Ar 2 are independently selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 10 , SR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • X 1 is selected from CR’ and N, wherein R’ is selected from hydrogen, F, Cl, CH 3 , CF 3 , and cyclopropyl.
  • X 2 , X 3 , and X 4 are independently selected from C and N.
  • X is selected from a bond, CH 2 , CH 2 CH 2 , CO, CH 2 CO, CONH, CONCH 3 , CH 2 O, CH 2 NH, and CH 2 NCH 3 .
  • R 1 and R 2 are independently selected from hydrogen, F, Cl, OH, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl.
  • X is CH 2 ; and Ar 1 is 3-fluorophenyl.
  • R 3 is connected to the linker moiety of the bivalent compound directly, and R 3 is selected from null, a bond, -OR 5 -, -SR 5 -, -NR 6 R 7 -, -COR 5 -, -CO 2 R 5 -, -CONR 6 R 7 -, -SOR 5 -, -SO 2 R 5 -, -SO 2 NR 6 R 7 -, -NR 5 COR 7 -, -NR 5 COR 7 -, -NR 5 COR 7 -, -NR 5 C (O) NR 6 R 7 -, -NR 5 SOR 7 -, -NR 5 SO 2 R 7 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkyleene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted
  • R 5 , R 6 and R 7 are independently selected from null, a bond, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-alkylene, optionally substituted C 1 -C 8 alkylene
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R 3 is connected to the linker moiety of the bivalent compound through R 4 .
  • R 3 and R 4 are independently selected from null, a bond, -OR 5 -, -SR 5 -, -NR 6 R 7 -, -COR 5 -, -CO 2 R 5 -, -CONR 6 R 7 -, -SOR 5 -, -SO 2 R 5 -, -SO 2 NR 6 R 7 -, -NR 5 COR 7 -, -NR 5 C (O) NR 6 R 7 -, -NR 5 SOR 7 -, -NR 5 SO 2 R 7 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alky
  • R 5 , R 6 and R 7 are independently selected from null, a bond, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-alkylene, optionally substituted C 1 -C 8 alkylene
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • Ar 1 is selected from C 6 -C 10 aryl and C 5 -C 10 heteroaryl, each of which is optionally substituted with one or more substituents independently selected from F, Cl, CN, NO 2 , OR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl, optionally substituted C
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • Ar 2 is selected from C 6 -C 10 aryl and C 5 -C 10 heteroaryl, each of which is optionally substituted with one or more substituents independently selected from F, Cl, CN, NO 2 , OR 13 , NR 14 R 15 , COR 13 , CO 2 R 13 , CONR 14 R 15 , SOR 13 , SO 2 R 13 , SO 2 NR 14 R 15 , NR 13 COR 14 , NR 13 C (O) NR 14 R 15 , NR 13 SOR 14 , NR 13 SO 2 R 14 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl, optionally substituted C
  • R 13 , R 14 , and R 15 are independently selected from null, hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 14 and R 15 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R 3 -Ar 2 is selected from a moiety of formulae B1 and B2:
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently selected from CH and N, with the proviso that up to 3 of Y 1 , Y 2 , Y 3 , and Y 4 are N;
  • each R a is independently selected from hydrogen, halogen, CN, NO 2 , OR 13 , NR 14 R 15 , COR 13 , CO 2 R 13 , CONR 14 R 15 , SOR 13 , SO 2 R 13 , SO 2 NR 14 R 15 , NR 13 COR 14 , NR 13 C (O) NR 14 R 15 , NR 13 SOR 14 , NR 13 SO 2 R 14 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2
  • R 13 , R 14 , and R 15 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 14 and R 15 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • n 0 to 4.
  • R 3 is the same as defined in Formula 2.
  • R 3 -Ar 2 is selected from a moiety of formula B3:
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently selected from CR a , N, O, and S, with the proviso that up to 3 of Y 1 , Y 2 , Y 3 , and Y 4 are N;
  • each R a is independently selected from hydrogen, halogen, CN, NO 2 , OR 13 , NR 14 R 15 , COR 13 , CO 2 R 13 , CONR 14 R 15 , SOR 13 , SO 2 R 13 , SO 2 NR 14 R 15 , NR 13 COR 14 , NR 13 C (O) NR 14 R 15 , NR 13 SOR 14 , NR 13 SO 2 R 14 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2
  • R 13 , R 14 , and R 15 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 14 and R 15 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • n 0 to 4.
  • R 3 is the same as defined in Formula 2.
  • X 1 is N; X 2 is N; X 3 is C; X 4 is C; and X is CH 2 .
  • Ar 1 is 3-fluorophenyl.
  • Ar 2 is 2-pyridyl
  • R 3 is selected from optionally substituted
  • the TRK ligand comprises a moiety of FORMULA 3:
  • X 1 , X 2 , X 3 , and X 4 are independently selected from C, CR’, and N (preferably, X 1 and X 4 are independently selected from CR’ and N; X 2 and X 3 are independently selected from C and N) , wherein
  • R’ is selected from hydrogen, halogen, CN, NO 2 , and optionally substituted C 1 -C 6 alkyl, C 3 -C 6 carbocyclyl, or 3-6 membered heterocyclyl;
  • X is selected from null, a bond, C (R 2 ) 2 , C (R 2 ) 2 C (R 2 ) 2 , CO, C (R 2 ) 2 CO, NR 2 CO, OC (R 2 ) 2 , and NR 2 C (R 2 ) 2 ;
  • R 1 and each R 2 are independently selected from hydrogen, halogen, OH, NH 2 , CN, NO 2 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 alkoxyalkyl, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 1 -C 4 hydroxyalkyl, optionally substituted C 1 -C 4 alkylaminoC 1 -C 4 alkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl;
  • n 1 to 4.
  • R 3 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, and optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl;
  • R 4 is connected to the linker moiety of the bivalent compound either directly or through R 5 , wherein
  • R 4 and R 5 are independently selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl)
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene- N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 10 , SR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl rings.
  • X 1 and X 4 is selected from CR’ and N, and R’ is selected from hydrogen, F, Cl, CH 3 , CF 3 , and cyclopropyl.
  • X 1 is N.
  • X 4 is CH.
  • X 2 and X 3 are independently selected from C and N.
  • X 2 is C and X 3 is N.
  • X 3 is C and X 2 is N.
  • X is selected from a bond, CH 2 , CH 2 CH 2 , CO, CH 2 CO, CONH, CONCH 3 , CH 2 O, CH 2 NH, and CH 2 NCH 3 .
  • X is CH 2 .
  • R 1 and each R 2 are independently selected from hydrogen, F, Cl, OH, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl.
  • R 1 and R 2 are hydrogen.
  • R 3 is selected from hydrogen, CH 3 , CH 2 CH 3 , propyl, isopropyl, cyclopropyl, CH 2 F, CHF 2 , and CF 3 .
  • R 3 is selected from hydrogen.
  • R 4 is connected to the linker moiety of the bivalent compound directly, and R 4 is selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • R 4 is connected to the linker moiety of the bivalent compound through R 5 , and R 4 and R 5 are independently selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R 4 and R 5 are independently selected from null, optionally substituted
  • R 4 and R 5 are independently selected from null, optionally substituted
  • -R 4 -R 5 - is selected from null, optionally substituted
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from F, Cl, CN, NO 2 , OR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • Ar is aryl, which is optionally substituted with one or more substituents independently selected from F, Cl, Br, CN, and NO 2 .
  • the TRK ligand comprises a moiety of FORMULA 3A:
  • X 1 is selected from CR’ and N;
  • R’ is selected from hydrogen, halogen, CN, NO 2 , and optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, C 3 -C 6 carbocyclyl, or 3-6 membered heterocyclyl;
  • X 2 and X 3 are selected from either C or N, with the proviso that only one of X 2 and X 3 is N;
  • X is selected from null, a bond, C (R 2 ) 2 , C (R 2 ) 2 C (R 2 ) 2 , CO, C (R 2 ) 2 CO, NR 2 CO, OC (R 2 ) 2 , and NR 2 C (R 2 ) 2 ;
  • R 1 and each R 2 are independently selected from hydrogen, halogen, OH, NH 2 , CN, NO 2 , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 alkoxyalkyl, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 1 -C 4 hydroxyalkyl, optionally substituted C 1 - C 4 alkylaminoC 1 -C 4 alkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl;
  • n 1 to 4.
  • R 3 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, and optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl;
  • R 4 is connected to the linker moiety of the bivalent compound either directly or through R 5 ;
  • R 4 and R 5 are independently selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 al
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 10 , SR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl rings.
  • X 1 and X 3 are selected from CR’ and N, and R’ is selected from hydrogen, F, Cl, CH 3 , CF 3 , and cyclopropyl.
  • X 1 is N.
  • X 1 is CR’ and R’ is selected from hydrogen, F, Cl, CH 3 , CF 3 , and cyclopropyl.
  • X 2 is C and X 3 is N.
  • X 3 is C and X 2 is N.
  • X is selected from a bond, CH 2 , CH 2 CH 2 , CO, CH 2 CO, CONH, CONCH 3 , CH 2 O, CH 2 NH, and CH 2 NCH 3 .
  • X is CH 2 .
  • R 1 and each R 2 are independently selected from hydrogen, F, Cl, OH, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl.
  • R 1 and R 2 are hydrogen.
  • R 3 is selected from hydrogen, CH 3 , CH 2 CH 3 , propyl, isopropyl, cyclopropyl, CH 2 F, CHF 2 , and CF 3 .
  • R 3 is selected from hydrogen.
  • R 4 is connected to the linker moiety of the bivalent compound directly, and R 4 is selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • R 4 is connected to the linker moiety of the bivalent compound through R 5 , and R 4 and R 5 are independently selected from null, -OR 6 -, -SR 6 -, -N (R 7 ) R 6 -, -COR 6 -, -CO 2 R 6 -, -CON (R 7 ) R 6 -, -SOR 6 -, -SO 2 R 6 -, -SO 2 N (R 7 ) R 6 -, -NR 8 COR 6 -, -N (R 8 ) C (O) N (R 7 ) R 6 -, -NR 8 SOR 6 -, -NR 8 SO 2 R 6 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1
  • R 6 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 6 and R 7 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • R 4 and R 5 are independently selected from null, optionally substituted
  • R 4 and R 5 are independently selected from null, optionally substituted
  • -R 4 -R 5 - is selected from null, optionally substituted
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from F, Cl, CN, NO 2 , OR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally
  • R 10 , R 11 , and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • Ar is aryl, which is optionally substituted with one or more substituents independently selected from F, Cl, Br, CN, and NO 2 .
  • the TRK ligand comprises a moiety of FORMULAE 12-1 or 12-2:
  • X is selected from CR 5 , and N;
  • Y is selected from O, S, and NR 6 ;
  • R 1 , R 3 and R 4 are independently selected from hydrogen, halogen, CN, NO 2 , OR 7 , SR 7 , NR 8 R 9 , COR 7 , CO 2 R 7 , CONR 8 R 9 , SOR 7 , SO 2 R 7 , SO 2 NR 8 R 9 , NR 10 COR 9 , NR 10 C (O) NR 8 R 9 , NR 10 SOR 9 , NR 10 SO 2 R 9 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered
  • R 7 , R 8 , R 9 , and R 10 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl-O-, optionally substituted 3-8 membered
  • R 8 and R 9 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • R 1 ’, R 2 , and R 4 ’ are independently selected from null, -OR 11 -, -SR 11 -, -NR 12 R 11 -, -COR 11 -, -CO 2 R 11 -, -CON (R 12 ) R 11 -, -SOR 11 -, -SO 2 R 11 -, -SO 2 N (R 12 ) R 11 -, -NR 13 COR 11 -, -NR 13 C (O) N (R 12 ) R 11 -, - NR 13 SOR 11 -, -NR 13 SO 2 R 11 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C
  • R 11 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclylene, optionally substituted C 3 -C 8 carbocyclylene-O-, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkylene, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkylene, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl-
  • R 12 and R 13 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 11 and R 12 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • R 5 and R 6 are independently selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl, and optionally substituted C 3 -C 8 heterocyclyl; and
  • n is selected from 0, 1, and 2.
  • X is selected from CH, CF, and N.
  • X is CH.
  • X is CF
  • X is N.
  • Y is selected from O and S.
  • Y is O.
  • Y is S.
  • R 1 is selected from optionally substituted acyclic amino, optionally substituted cyclic amino, optionally substituted phenyl, and optionally substituted heteroaryl.
  • R 1 is selected from optionally substituted
  • R 1 ’ is selected from null, optionally substituted acyclic amino, optionally substituted cyclic amino, optionally substituted phenyl, and optionally substituted heteroaryl.
  • R 1 ’ is selected from optionally substituted
  • R 2 is selected from null, -O-, -S-, -N (R 12 ) -, -C (O) -, -CO 2 -, -CON (R 12 ) -, -SO-, -SO 2 -, -SO 2 N (R 12 ) -, -N (R 13 ) CO-, -N (R 13 ) C (O) N (R 12 ) -, -N (R 13 ) SO-, -N (R 13 ) SO 2 -, optionally substituted optionally substituted C 3 -C 8 carbocyclyl, and optionally substituted C 3 -C 8 heterocyclyl, wherein
  • R 12 , and R 13 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • R 2 is selected from null, -CONH-,
  • R 3 is selected from hydrogen, halogen, CN, NO 2 , OH, NH 2 , -CONH-,
  • R 2 -R 3 is selected from hydrogen, halogen, CN, NO 2 ,
  • R 4 is selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkyl, and optionally substituted 3
  • R 4 is selected from hydrogen, halogen, CN, NO 2 , OCH 3 ,
  • R 4 ’ is selected from null, -O-, -S-, -N (R 12 ’) -, -C (O) -, -CO 2 -, -CON (R 12 ’) -, -SO-, -SO 2 -, -SO 2 N (R 12 ’) -, -N (R 12 ’) CO-, -N (R 13 ’) C (O) N (R 12 ’) -, -N (R 13 ’) SO-, -N (R 13 ’) SO 2 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylene-N (
  • R 12 ’, and R 13 ’ are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • R 4 ’ is selected from null, -O-, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkylene, and optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkylene, optionally substituted 3-8 membered carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl-O-, optionally substituted 3-8 membered carbocyclyl-N (C 1 -C 8 alkyl) -
  • R 4 ’ is selected null, -O-,
  • the TRK ligand comprises a moiety of FORMULA 13:
  • X is selected from CR 9 , and N;
  • R 9 is selected from from hydrogen, halogen, CN, NO 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl, and optionally substituted C 3 -C 8 heterocyclyl;
  • Y is selected from null, -O-. -N (optionally substituted C 1 -C 8 alkyl) -, and optionally substituted C 1 -C 8 alkylene;
  • R 1 and R 2 are independently selected from hydrogen, halogen, CN, NO 2 , OH, NH 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl, and optionally substituted C 3 -C 8 heterocyclyl;
  • R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, halogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl, and optionally substituted C 3 -C 8 heterocyclyl; or
  • n is selected from 1, 2, 3, and 4;
  • n is selected from 0, 1, 2, 3, and 4;
  • R 7 and R 8 are independently selected from null, -OR 10 -, -SR 10 -, -NR 11 R 10 -, -COR 10 -, -CO 2 R 10 -, -CONR 11 R 10 -, -SOR 10 -, -SO 2 R 10 -, -SO 2 NR 11 R 10 -, -NR 12 COR 10 -, -NR 12 C (O) NR 11 R 10 -, -NR 12 SOR 10 -, -NR 12 SO 2 R 10 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -
  • R 10 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclylene, optionally substituted C 3 -C 8 carbocyclylene-O-, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkylene, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkylene, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl-
  • R 11 and R 12 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl-C 1 -C 8 alkyl, optionally substituted 3-8 membered heterocyclyl-C 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbo
  • R 10 and R 11 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 14 , SR 14 , NR 15 R 16 , COR 14 , CO 2 R 14 , CONR 15 R 16 , SOR 14 , SO 2 R 14 , SO 2 NR 15 R 16 , NR 14 COR 16 , NR 14 C (O) NR 15 R 16 , NR 14 SOR 16 , NR 14 SO 2 R 16 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7
  • R 14 , R 15 , and R 16 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R 15 and R 16 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl rings.
  • the TRK ligand comprises a moiety of FORMULA 13-1:
  • X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ar, m, and n are defined in FORMULA 13.
  • the TRK ligand comprises a moiety of FORMULA 13-2:
  • X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Ar are defined in FORMULA 13.
  • X is selected from CH, CF and N.
  • X is N.
  • Y is selected from -O-, -CH 2 -and -NH-.
  • Y is -O-.
  • R 1 is selected from hydrogen and NH 2 .
  • R 1 is NH 2 .
  • R 2 is selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 carbocyclyl, and optionally substituted C 1 -C 8 alkoxy.
  • R 2 is selected from H, F, Cl, Br, OCH 3 , OCF 3 , and OCHF 2 .
  • R 2 is OCH 3 .
  • R 3 , R 4 , R 5 , and R 6 are independently selected from H, F, CH 3 , cyclopropyl, and cyclobutyl.
  • R 3 and R 4 ; and/or R 5 and R 6 together with the atom to which they are connected optionally form , cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • R 3 , R 4 , R 5 , and R 6 are H.
  • R 7 is selected from null, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • R 7 is selected from null
  • R 8 is selected from null, -C (O) -, -C (O) -NH-, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • R 8 is selected from null, -C (O) -, -C (O) -NH-,
  • R 7 -R 8 is selected from null
  • Ar is selected from optional substituted phenyl, and optional substituted pyridinyl.
  • Ar is selected from
  • the TRK ligand is derived from any of the following:
  • the TRK ligand is derived from the following TRK kinase inhibitors: DS-6051b, F17752, PLX7486, AZD-6918, ASP7962, VM902A, PF-06273340, and ONO-4474.
  • the TRK ligand is selected from the group consisting of:
  • the degradation tag is a moiety selected from the group consisting of FORMULAE 5A, 5B, 5C, and 5D:
  • V, W, and X are independently selected from CR 2 and N;
  • R 1 is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • R 2 is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 alkylamino, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • R 3 , and R 4 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl; or R 3 and R 4 together with the atom to which they are connected form a 3-6 membered carbocyclyl, or 3-6 membered heterocyclyl; and
  • R 5 and R 6 are independently selected from null, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl; or R 5 and R 6 together with the atom to which they are connected form a 3-6 membered carbocyclyl, or 3-6 membered heterocyclyl.
  • the degradation tag is a moiety selected from the group consisting of FORMULAE 5E, 5F, 5G, 5H, 5I, 5J, 5K, 5L, 5M, 5N, 5O, 5P, and 5Q:
  • U, V, W, X and X’ are independently selected from CR 2 and N;
  • Y is selected from CR 3 R 4 , NR 3 and O; preferly, Y is selected from CH 2 , NH, NCH 3 and O;
  • Y’, Y”, and Y”’ are independently selected from CR 3 R 4 ;
  • R 1 is independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • R 2 is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 alkylamino, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • R 3 , and R 4 are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl, or
  • R 3 and R 4 together with the atom to which they are connected optionally form a 3-6 membered carbocyclyl, or 3-6 membered heterocyclyl;
  • R 5 and R 6 are independently selected from null, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl; or R 5 and R 6 together with the atom to which they are connected form a 3-6 membered carbocyclyl, or 3-6 membered heterocyclyl.
  • the degradation tag is a moiety of FORMULA 6A:
  • R 1 and R 2 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted C 2 -C 8 alkynyl; and
  • R 3 is hydrogen, optionally substituted C (O) C 1 -C 8 alkyl, optionally substituted C (O) C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C (O) C 1 -C 8 haloalkyl, optionally substituted C (O) C 1 -C 8 hydroxyalkyl, optionally substituted C (O) C 1 -C 8 aminoalkyl, optionally substituted C (O) C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C (O) C 3 -C 7 carbocyclyl, optionally substituted C (O) (3-7 membered heterocyclyl) , optionally substituted C (O) C 2 -C 8 alkenyl, optionally substituted C (O) C 2 -C 8 alkynyl, optionally substituted C (O) OC 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C (O)
  • the degradation tag is a moiety selected from the group consisting of FORMULAE 6B, 6C, 6D, 6E and 6F:
  • R 1 and R 2 are independently selected from hydrogen, halogen, OH, NH 2 , CN, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted C 2 -C 8 alkynyl; (preferably, R 1 is selected from iso-propyl or tert-butyl; and R 2 is selected from hydrogen or methyl) ; .
  • R 3 is hydrogen, optionally substituted C (O) C 1 -C 8 alkyl, optionally substituted C (O) C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C (O) C 1 -C 8 haloalkyl, optionally substituted C (O) C 1 -C 8 hydroxyalkyl, optionally substituted C (O) C 1 -C 8 aminoalkyl, optionally substituted C (O) C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C (O) C 3 -C 7 carbocyclyl, optionally substituted C (O) (3-7 membered heterocyclyl) , optionally substituted C (O) C 2 -C 8 alkenyl, optionally substituted C (O) C 2 -C 8 alkynyl, optionally substituted C (O) OC 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C (O)
  • R 4 and R 5 are independently selected from hydrogen, COR 6 , CO 2 R 6 , CONR 6 R 7 , SOR 6 , SO 2 R 6 , SO 2 NR 6 R 7 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein
  • R 6 and R 7 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • Ar is selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from F, Cl, CN, NO 2 , OR 8 , NR 8 R 9 , COR 8 , CO 2 R 8 , CONR 8 R 9 , SOR 8 , SO 2 R 8 , SO 2 NR 8 R 9 , NR 10 COR 8 , NR 10 C (O) NR 8 R 9 , NR 10 SOR 8 , NR 10 SO 2 R 8 , optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3
  • R 8 , R 9 , and R 10 are independently selected from null, hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 8 and R 9 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • the degradation tag is a moiety of FORMULA 7A:
  • V, W, X, and Z are independently selected from CR 4 and N.
  • R 1 , R 2 , R 3 , and R 4 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted C 2 -C 8 alkynyl.
  • the degradation tag is a moiety of FORMULA 7B:
  • R 1 , R 2 , and R 3 are independently selected from hydrogen, halogene, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, and optionally substituted C 2 -C 8 alkynyl;
  • R 4 and R 5 are independently selected from hydrogen, COR 6 , CO 2 R 6 , CONR 6 R 7 , SOR 6 , SO 2 R 6 , SO 2 NR 6 R 7 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted aryl-C 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein
  • R 6 and R 7 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 6 and R 7 together with the atom to which they are connected form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • the degradation tag is derived from any of the following:
  • the degradation tag is derived from any of the following: thalidomide, pomalidomide, lenalidomide, CRBN-1, CRBN-2, CRBN-3, CRBN-4, CRBN-5, CRBN-6, CRBN-7, CRBN-8, CRBN-9, CRBN-10, and CRBN-11.
  • the degradation tag is selected from the group consisting of:
  • the degradation tag is selected from the group consisting of: FORMULA 8A, 8B, 8C, 8D, 8E, 8F, 8G, 8H, 8I, 8J, 8K, 8L, 8M, 8O, 8P, 8Q, 8R, 8AQ, 8AR, 8AS, 8AT, 8AU, 8AV, 8AW, 8AX, 8AY, 8AZ, 8BA, 8BB, 8BC, 8BD, 8BE, 8BF, 8BG, 8BH, 8BI, 8BJ, 8BK, 8BL, 8BM, and 8BN, 8BO, 8BP, 8BQ, 8BR, 8BS, 8CB, 8CC, 8CD, 8CE, 8CF, 8CG, 8CH, 8CI, 8CJ, 8CK, 8CL, 8CM, 8CN, 8CO, 8CP, 8CQ, 8CR, 8CS, 8CT, 8CU, 8CV, 8CW, 8CX, 8CY, 8CZ, 8DA, 8DB, 8DC, 8DD,
  • the linker moiety is of FORMULA 9:
  • A, W and B, at each occurrence, are independently selected from null, or bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 1 ) R”, R’C (S) N (R 1 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 1 ) R”, R’N (R 1 ) R”, R”N (R 1 ) COR”, R’N (R 1 ) CON (R 2 ) R”, R’N (R 1 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substitute
  • R’ and R” are independently selected from null, optionally substituted (C 1 -C 8 alkylene) -R r (preferably, CH 2 -R r ) , optionally substituted R r - (C 1 -C 8 alkylene) , optionally substituted (C 1 -C 8 alkylene) -R r - (C 1 -C 8 alkyl) , or a moiety comprising of optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally
  • R r is selected from optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 1 and R 2 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • m 0 to 15.
  • the linker moiety is of FORMULA 9A:
  • R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylamino, and optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-10 membered carbocyclylamin
  • R 1 and R 2 , or R 3 and R 4 together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • A, W and B, at each occurrence, are independently selected from null, or bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 5 ) R”, R’C (S) N (R 5 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 5 ) R”, R’N (R 5 ) R”, R’N (R 5 ) COR”, R’N (R 5 ) CON (R 6 ) R”, R’N (R 5 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substitute
  • R’ and R” are independently selected from null, optionally substituted (C 1 -C 8 alkylene) -R r (preferably, CH 2 -R r ) , optionally substituted R r - (C 1 -C 8 alkylene) , optionally substituted (C 1 -C 8 alkylene) -R r - (C 1 -C 8 alkylene) , or a moiety comprising of optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally
  • R r is selected from optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 5 and R 6 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • n 0 to 15;
  • n at each occurrence, is 0 to 15;
  • o 0 to 15.
  • linker moiety is of FORMULA 9B:
  • R 1 and R 2 are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, and optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxy C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylamino, C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-10 membered carbocyclylamino, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 1 and R 2 together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • a and B are independently selected from null, or bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 3 ) R”, R’C (S) N (R 3 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 3 ) R”, R’N (R 3 ) R”, R’N (R 3 ) COR”, R’N (R 3 ) CON (R 4 ) R”, R’N (R 3 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1
  • R’ and R” are independently selected from null, optionally substituted (C 1 -C 8 alkylene) -R r (preferably, CH 2 -R r ) , optionally substituted R r - (C 1 -C 8 alkylene) , optionally substituted (C 1 -C 8 alkylene) -R r - (C 1 -C 8 alkylene) , or a moiety comprising of optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally
  • R r is selected from optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 3 and R 4 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • each m is 0 to 15;
  • n 0 to 15.
  • linker moiety is of FORMULA 9C:
  • X is selected from O, NH, and NR 7 ;
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxy C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-8 membered cycloalkoxy,
  • a and B are independently selected from null, or bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 8 ) R”, R’C (S) N (R 8 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 8 ) R”, R’N (R 8 ) R”, R’N (R 8 ) COR”, R’N (R 8 ) CON (R 9 ) R”, R’N (R 8 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8
  • R’ and R” are independently selected from null, optionally substituted (C 1 -C 8 alkylene) -R r (preferably, CH 2 -R r ) , optionally substituted R r - (C 1 -C 8 alkylene) , optionally substituted (C 1 -C 8 alkylene) -R r - (C 1 -C 8 alkylene) , or a moiety comprising of optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally
  • R r is selected from optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 7 , R 8 and R 9 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • n 0 to 15;
  • n at each occurrence, is 0 to 15;
  • o 0 to 15;
  • p 0 to 15.
  • m and n is 0 or 1, and p is 0 to 15;
  • X is selected from O and NH;
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, and optionally substituted C 1 -C 6 alkyl.
  • the linker moiety comprises one or more rings selected from the group consisting of 3 to 13 membered rings, 4 to 13 membered fused rings, 5 to 13 membered bridged rings, and 5 to13 membered spiro rings.
  • the linker moiety comprises a ring selected from the group consisting of Formula C1, C2, C3, C4 and C5:
  • X’ and Y’ are independently selected from N and CR b ;
  • a 1 , B 1 , C 1 and D 1 are independently selected from null, O, CO, SO, SO 2 , NR b , and CR b R c ;
  • a 2 , B 2 , C 2 , and D 2 at each occurrence, are independently selected from N and CR b ;
  • a 3 , B 3 , C 3 , D 3 , and E 3 at each occurrence, are independently selected from N, O, S, NR b , and CR b ;
  • R b and R c are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylamino, and optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-10 membered carbocyclylamino, optionally substituted
  • n 1 , o 1 and p 1 are independently selected from 0, 1, 2, 3, 4 and 5.
  • A, B and W, at each occurrence, are independently selected from null, optionally substituted - (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-8 -CO- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-8 -NH- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-8 -NH-CO- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0- 8 -CO-NH- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-3 -NH- (CH 2 ) 0-3 -CO-NH- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-3 -NH- (CH 2 ) 0-3 -CO-NH- (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0
  • R r is of Formula C1, C2, C3, C4 or C5.
  • R r is selected from
  • the length of the linker is 0 to 40 atoms.
  • the length of the linker is 0 to 20 atoms.
  • the length of the linker is 0 to 10 atoms.
  • the linker is selected from null, optionally substituted - (CO) - (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-9 -, optionally substituted - (CH 2 ) 1-2 - (CO) -NH- (CH 2 ) 0-9 -, optionally substituted - (CH 2 ) 1-2 - (CO) -NH- (CH 2 ) 1-3 - (OCH 2 CH 2 ) 1-7 -, optionally substituted - (CH 2 ) 0-1 - (CO) - (CH 2 ) 1-3 - (OCH 2 CH 2 ) 1-7 -, optionally substituted - (CO) - (CH 2 ) 0-3 - (alkenylene) - (CH 2 ) 0-3 -, optionally substituted - (CO) - (CH 2 ) 0-3 - (alkynylene) - (CH 2 ) 0-3 -, optionally
  • a bivalent compound comprising a Tropomyosin Receptor Kinase (TRK) ligand conjugated to a degradation tag via a linker, or a pharmaceutically acceptable salt or analog thereof, wherein the linker and the degradation tag are each independently selected from those disclosed herein, and the TRK ligand is a moiety of Formula 10 which connects to the linker via R 4 :
  • TRK Tropomyosin Receptor Kinase
  • X 1 , X 2 , X 3 , X 4 , and X 5 are each independently selected from C, CR 1 , and N;
  • X is selected from CR 1 R 2 , CO, O, S, SO, SO 2 , and NR 1 ;
  • R is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, and Ar 1 ; or
  • U is selected from null, a bond, C (R 2 ) 2 , C (R 2 ) 2 C (R 2 ) 2 , CO, C (R 2 ) 2 CO, CONR 2 , C (R 2 ) 2 O, C (R 2 ) 2 NR 2 and CH 2 NR 2 ;
  • R 1 and R 2 are independently selected from hydrogen, halogen, CN, NO 2 , OR 6 , SR 6 , NR 7 R 8 , COR 6 , CO 2 R 6 , C (O) NR 7 R 8 , SOR 6 , SO 2 R 6 , SO 2 NR 7 R 8 , NR 6 C (O) R 8 , NR 6 C (O) NR 7 R 8 , NR 6 SOR 8 , NR 6 SO 2 R 8 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, optionally
  • R 1 and R 2 , R 1 and another R 1 , or R 2 and another R 2 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • R 6 , R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 7 and R 8 together with the atom to which they are connected, optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • n 0, 1, 2, 3, or 4;
  • n’ is 0, 1, 2, or 3;
  • L is Ar 2 , NR 3 CO or NR 3 COAr 2 ;
  • R 3 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, and optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl;
  • R 4 is connected to the linker moiety of the bivalent compound either directly or through R 5 , wherein
  • R 4 and R 5 are bivalent groups independently selected from null, -O-, -S-, -NR 9 -, -CO-, -CO 2 -, -CONR 9 -, -SO-, -SO 2 R 9 -, -SO 2 NR 9 -, -NR 10 CO-, -NR 10 C (O) NR 9 -, -NR 10 SO-, -NR 10 SO 2 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclylene, optionally substituted 3-8 membered heterocyclylene, optional
  • R 9 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 10 is selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • Ar 1 and Ar 2 are independently selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 11 , SR 11 , NR 12 R 13 , COR 11 , CO 2 R 11 , CONR 12 R 13 , SOR 11 , SO 2 R 11 , SO 2 NR 12 R 13 , NR 11 COR 13 , NR 11 C (O) NR 12 R 13 , NR 11 SOR 13 , NR 11 SO 2 R 13 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C
  • R 11 , R 12 , and R 13 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or
  • R 12 and R 13 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • a bivalent compound comprising a Tropomyosin Receptor Kinase (TRK) ligand conjugated to a degradation tag via a linker, or a pharmaceutically acceptable salt or analog thereof, wherein TRK ligand and the linker are each independently selected from those disclosed herein, and the degradation tag is a moiety of Formula 11 which connects to the linker via Z or any of V 1 , V 2 , V 3 , V 4 , W 1 , W 2 , and W 3 :
  • TRK Tropomyosin Receptor Kinase
  • V 1 , V 2 , V 3 , and V 4 are each independently selected from CR 2’ and N;
  • W 1 , W 2 , and W 3 are each independently selected from CO, O, CR 3’ R 4’ , and NR 5’ , wherein R 5’ is selected from a hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, and 2, 6-dioxopiperidin-3-yl optionally substituted with R 1’ , provided that there are no two adjacent CO groups;
  • Z is selected from null, CO, CR 3’ R 4’ , NR 3’ , O, optionally substituted C 1 -C 10 alkylene, optionally substituted C 1 -C 10 heteroalkylene, optionally substituted C 2 -C 10 alkenylene, optionally substituted C 2 -C 10 alkynylene, optionally substituted 3-7 membered carbocyclyl, and optionally substituted 3-7 membered heterocyclyl;
  • R 1’ is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl;
  • R 2’ is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 alkylamino, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl; and
  • R 3’ and R 4’ at each occurance are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3-6 membered carbocyclyl, and optionally substituted 3-6 membered heterocyclyl; or
  • R 3’ and R 4’ together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • a bivalent compound comprising a Tropomyosin Receptor Kinase (TRK) ligand conjugated to a degradation tag via a linker, or a pharmaceutically acceptable salt or analog thereof, wherein the TRK ligand and the degradation tag are each independently selected from those disclosed herein, and the linker is a moiety of Formula 9:
  • TRK Tropomyosin Receptor Kinase
  • a and B are independently selected from null, or a bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 1” ) R”, R’C (S) N (R 1” ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 1” ) R”, R’N (R 1” ) R”, R”N (R 1” ) COR”, R”N (R 1” ) CON (R 2” ) R”, R’N (R 1” ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 halo
  • each W is independently selected from null, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally
  • R 1 and R 2 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • a bivalent compound comprising a Tropomyosin Receptor Kinase (TRK) ligand conjugated to a degradation tag via a linker, or a pharmaceutically acceptable salt or analog thereof, wherein the TRK ligand is a moiety of Formula 10 which connects to the linker via R 4 :
  • TRK Tropomyosin Receptor Kinase
  • X 1 , X 2 , X 3 , X 4 , and X 5 are each independently selected from C, CR 1 , and N;
  • X is selected from CR 1 R 2 , CO, O, S, SO, SO 2 , and NR 1 ;
  • R is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, and Ar 1 ; or
  • U is selected from null, a bond, C (R 2 ) 2 , C (R 2 ) 2 C (R 2 ) 2 , CO, C (R 2 ) 2 CO, CONR 2 , C (R 2 ) 2 O, C (R 2 ) 2 NR 2 and CH 2 NR 2 ;
  • R 1 and R 2 are independently selected from hydrogen, halogen, CN, NO 2 , OR 6 , SR 6 , NR 7 R 8 , COR 6 , CO 2 R 6 , C (O) NR 7 R 8 , SOR 6 , SO 2 R 6 , SO 2 NR 7 R 8 , NR 6 C (O) R 8 , NR 6 C (O) NR 7 R 8 , NR 6 SOR 8 , NR 6 SO 2 R 8 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, optionally
  • R 1 and R 2 , R 1 and another R 1 , or R 2 and another R 2 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • R 6 , R 7 and R 8 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 7 and R 8 together with the atom to which they are connected, optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • n 0, 1, 2, 3, or 4;
  • n’ is 0, 1, 2, or 3;
  • L is Ar 2 , NR 3 CO or NR 3 COAr 2 ;
  • R 3 is selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted C 1 -C 6 alkoxyalkyl, optionally substituted C 1 -C 6 haloalkyl, optionally substituted C 1 -C 6 hydroxyalkyl, and optionally substituted C 1 -C 6 alkylaminoC 1 -C 6 alkyl;
  • R 4 is connected to the linker moiety of the bivalent compound either directly or through R 5 , wherein
  • R 4 and R 5 are bivalent groups independently selected from null, -O-, -S-, -NR 9 -, -CO-, -CO 2 -, -CONR 9 -, -SO-, -SO 2 R 9 -, -SO 2 NR 9 -, -NR 10 CO-, -NR 10 C (O) NR 9 -, -NR 10 SO-, -NR 10 SO 2 -, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclylene, optionally substituted 3-8 membered heterocyclylene, optional
  • R 9 is selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkylene-O-, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -, optionally substituted C 1 -C 8 alkylene-O-C 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylene-N (C 1 -C 8 alkyl) -C 1 -C 8 alkylene, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 carbocyclyl-O-, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 10 is selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, , optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • Ar 1 and Ar 2 are independently selected from aryl and heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 11 , SR 11 , NR 12 R 13 , COR 11 , CO 2 R 11 , CONR 12 R 13 , SOR 11 , SO 2 R 11 , SO 2 NR 12 R 13 , NR 11 COR 13 , NR 11 C (O) NR 12 R 13 , NR 11 SOR 13 , NR 11 SO 2 R 13 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C
  • R 11 , R 12 , and R 13 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 12 and R 13 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring;
  • the degradation tag is a moiety of Formula 11 which connects to the linker via Z or any of V 1 , V 2 , V 3 , V 4 , W 1 , W 2 , and W 3 :
  • V 1 , V 2 , V 3 , and V 4 are each independently selected from CR 2’ and N;
  • W 1 , W 2 , and W 3 are each independently selected from CO, O, CR 3’ R 4’ , and NR 5’ , wherein R 5’ is selected from a hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, and 2, 6-dioxopiperidin-3-yl optionally substituted with R 1’ , provided that there are no two adjacent CO groups;
  • Z is selected from null, CO, CR 3’ R 4’ , NR 3’ , O, optionally substituted C 1 -C 10 alkylene, optionally substituted C 1 -C 10 heteroalkylene, optionally substituted C 1 -C 10 alkenylene, optionally substituted C 1 -C 10 alkynylene, optionally substituted 3-7 membered carbocyclyl, and optionally substituted 3-7 membered heterocyclyl;
  • R 1’ is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered carbocyclyl, and optionally substituted 3 to 6 membered heterocyclyl;
  • R 2’ is selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 alkylamino, optionally substituted 3 to 6 membered carbocyclyl, and optionally substituted 3 to 6 membered heterocyclyl; and
  • R 3’ and R 4’ at each occurance are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered carbocyclyl, and optionally substituted 3 to 6 membered heterocyclyl; or
  • R 3’ and R 4’ together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • linker is a moiety of Formula 9:
  • a and B are independently selected from null, or a bivalent moiety selected from R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 1” ) R”, R’C (S) N (R 1” ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 1 ” ) R”, R’N (R 1” ) R”, R”N (R 1” ) COR”, R”N (R 1” ) CON (R 2” ) R”, R’N (R 1” ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 hal
  • each W is independently selected from null, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -C 13 bridged carbocyclyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted C 5 -C 13 spiro carbocyclyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally
  • R 1 and R 2 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and
  • n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • U is selected from a bond, CH 2 , CH 2 CH 2 , CO, CH 2 CO, CONH, CONCH 3 , CH 2 O, CH 2 NH, and CH 2 NCH 3 .
  • R 1 and R 2 are independently selected from hydrogen, F, Cl, OH, optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1 -C 4 alkoxy, optionally substituted C 1 -C 4 alkylamino, optionally substituted C 1 -C 4 haloalkyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted C 3 -C 6 cycloalkoxy, and optionally substituted 3-6 membered heterocyclyl.
  • R 1 and R 2 are independently selected from hydrogen, F, Cl, CH 3 , CF 3 , andcyclopropyl.
  • Ar 1 is selected from optionally substituted C 6 -C 10 aryl and optionally substituted C 5 -C 10 heteroaryl.
  • Ar 1 is selected from 3-fluorophenyl, 3, 5-difluorophenyl, and 2, 5-difluorophenyl.
  • L is Ar 2 and R 4 is connected to the linker moiety of the bivalent compound through R 5 .
  • L is Ar 2 and R 4 is connected to the linker moiety of the bivalent compound directly.
  • R 4 is selected from
  • L is Ar 2
  • Ar 2 is selected from optionally substituted C 6 -C 10 aryl and optionally substituted C 5 -C 10 heteroaryl.
  • L is Ar 2 or NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formulae B1, B2, and B3:
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently selected from CR a and N, with the proviso that up to 3 of Y 1 , Y 2 , Y 3 , and Y 4 are N;
  • each R a is independently selected from hydrogen, halogen, CN, NO 2 , OR 14 , NR 15 R 16 , COR 14 , CO 2 R 14 , CONR 15 R 16 , SOR 14 , SO 2 R 14 , SO 2 NR 15 R 16 , NR 14 COR 15 , NR 14 C (O) NR 15 R 16 , NR 14 SOR 15 , NR 14 SO 2 R 15 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C
  • R 14 , R 15 and R 16 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 15 and R 16 together with the atom to which they are connected, optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring.
  • L is Ar 2 or NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formula B4:
  • Y 1’ , Y 2’ , Y 3’ , and Y 4’ are independently selected from CR a , N, O, and S, with the proviso that up to 3 of Y 1’ , Y 2’ , Y 3’ , and Y 4’ are N;
  • each R a is independently selected from hydrogen, halogen, CN, NO 2 , OR 14 , NR 15 R 16 , COR 14 , CO 2 R 14 , CONR 15 R 16 , SOR 14 , SO 2 R 14 , SO 2 NR 15 R 16 , NR 14 COR 15 , NR 14 C (O) NR 15 R 16 , NR 14 SOR 15 , NR 14 SO 2 R 15 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 7 carbocyclyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C
  • R 14 , R 15 and R 16 are independently selected from null, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 6 carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted heterocarbocyclyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 15 and R 16 together with the atom to which they are connected, optionally form a 3-8 membered carbocyclyl or 3-8 membered heterocyclyl ring.
  • L is NR 3 CO
  • R 3 is selected from hydrogen, CH 3 , CH 2 CH 3 , propyl, isopropyl, cyclopropyl, CH 2 F, CHF 2 , and CF 3 .
  • L is NR 3 CO and R 4 is connected to the linker moiety of the bivalent compound directly.
  • L is NR 3 CO and R 4 is connected to the linker moiety of the bivalent compound through R 5 .
  • L is NR 3 COAr 2 , wherein R 3 is selected from hydrogen, CH 3 , CH 2 CH 3 , propyl, isopropyl, cyclopropyl, CH 2 F, CHF 2 , and CF 3 ; and Ar 2 is slected from optionally substituted C 6 -C 10 aryl and optionally substituted C 5 -C 10 heteroaryl.
  • L is NR 3 COAr 2 and R 4 is connected to the linker moiety of the bivalent compound directly.
  • L is NR 3 COAr 2 and R 4 is connected to the linker moiety of the bivalent compound through R 5 .
  • L is NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formulae B1, B2 and B3.
  • L is NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formula B1, where in Y 1 is CH or N.
  • L is NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formula B2, where in Y 1 is CR a , and R a is H,
  • L is NR 3 COAr 2 and Ar 2 -R 4 is selected from a moiety of formula B3, wherein Y 2 is is CR a , and R a is
  • L is NR 3 COAr 2 and X-R is X-Ar 1 .
  • L is NR 3 COAr 2 and X-R is X-Ar 1 , wherein X is CH 2 ; and Ar 1 is selected from 3-fluorophenyl, 3, 5-di fluorophenyl, or 2, 5-di fluorophenyl.
  • V 1 , V 2 , V 3 , and V 4 are each independently CR 2’ .
  • At least one of W 1 , W 2 , and W 3 is NR 5’ .
  • At least one of W 1 , W 2 , and W 3 is NR 5’ , and only one of R 5’ is 2, 6-dioxopiperidin-3-yl optionally substituted with R 1’ .
  • W 1 is CO.
  • W 2 is CO
  • W 3 is CO.
  • W 1 and W 3 are both CO.
  • W 2 is CO and W 1 and W 3 are both NR 5’ , and only one of R 5’ is 2, 6-dioxopiperidin-3-yl optionally substituted with R 1’ .
  • W at each occurance, is indepdently selected from Formulae C1, C2, C3, C4 and C5:
  • X’ and Y’ are independently selected from N, and CR b ;
  • a 1 , B 1 , C 1 , and D 1 are independently selected from null, O, CO, SO, SO 2 , NR b , and CR b R c ;
  • a 2 , B 2 , C 2 , and D 2 at each occurrence, are independently selected from N, and CR b ;
  • a 3 , B 3 , C 3 , D 3 , and E 3 at each occurrence, are independently selected from N, O, S, NR b , and CR b ;
  • R b and R c are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyalkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 alkylamino, and optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-8 membered cycloalkoxy, optionally substituted 3-10 membered carbocyclylamino, optionally substituted
  • n 1 , o 1 and p 1 are independently selected from 0, 1, 2, 3, 4 and 5.
  • the length of the linker is 3 to 40 atoms.
  • the length of the linker is 3 to 20 atoms.
  • the length of the linker is 3 to 10 atoms.
  • the linker is selected from optionally substituted - (CO) - (CH 2 ) 0-3 -W- (CH 2 ) 0-3 -, - (CH 2 ) 0-3 -W- (CH 2 ) 0-3 -, optionally substituted - (CO) - (CH 2 ) 0-8 -, optionally substituted - (CH 2 ) 0-9 -, optionally substituted - (CH 2 ) 1-2 - (CO) -NH- (CH 2 ) 2-9 -, optionally substituted - (CH 2 ) 1-2 - (CO) -NH- (CH 2 ) 1-3 - (OCH 2 CH 2 ) 1-7 -, optionally substituted - (CH 2 ) 0-1 - (CO) - (CH 2 ) 1-3 - (OCH 2 CH 2 ) 1-7 -, optionally substituted - (CO) - (CH 2 ) 0-3 -W- (CH 2 ) 0-3
  • the linker is selected from optionally substituted - (CO) - (CH 2 ) 0-3 - (3-8 membered carbocyclyl) - (CH 2 ) 0-3 -, optionally substituted - (CO) - (CH 2 ) 0-3 - (3-8 membered heterocyclyl) - (CH 2 ) 0-3 -, optionally substituted - (CH 2 ) 0-3 - (3-8 membered carbocyclyl) - (CH 2 ) 0-3 -, and optionally substituted - (CH 2 ) 0-3 - (3-8 membered heterocyclyl) - (CH 2 ) 0-3 -.
  • W is selected from
  • the bivalent compound is selected from the group consisting of CPD-001 to CPD-516, or a pharmaceutically acceptable salt or analog thereof.
  • the bivalent compound is selected from the group consisting of CPD-009, CPD-010, CPD-013, CPD-014, CPD-015, CPD-021, CPD-022, CPD-023, CPD-024, CPD-025, CPD-026, CPD-027, CPD-028, CPD-029, CPD-030, CPD-031, CPD-032, CPD-033, CPD-044, CPD-047, CPD-049, CPD-050, CPD-051, CPD-052, CPD-053, CPD-054, CPD-055, CPD-056, CPD-057, CPD-059, CPD-060, CPD-062, CPD-064, CPD-065, TR-104, TR-105, TR-106, TR-107, TR-108, TR-109, TR-113, TR-115, TR-116, TR-117, TR-118, TR-119, TR-120, TR-121, TR-122, TR-123,
  • the bivalent compound is selected from the group consisting of TR-106, TR-108, TR-109, TR-113, TR-115, TR-116, TR-117, TR-119, TR-121, TR-122, TR-123, TR-124, TR-125, TR-127, TR-128, TR-129, TR-130, TR-131, TR-132, TR-135, TR-137, TR-140, TR-141, TR-142, TR-143, TR-144, TR-145, TR-146, TR-149, TR-151, TR-152, TR-155, TR-156, TR-160, TR-161, TR-162, TR-165, TR-166, TR-167, TR-168, TR-169, TR-171, TR-172, TR-173, TR-176, TR-177, TR-181, TR-182, TR-184, TR-185, TR-186, TR-189, TR-190, TR-191, TR-194, TR-196, TR-198, TR-204, TR-208, TR-211, TR-216, TR-217,
  • the bivalent compound is selected from the group consisting of TR-123, TR-172, TR-173, TR-181, TR-182, TR-184, TR-185, TR-186, TR-191, TR-196, TR-198, TR-204, TR-221, TR-224, TR-225, TR-226, TR-231, TR-233, TR-241, TR-249, TR-254, TR-258, TR-259, TR-260, TR-263, TR-264, TR-265, TR-266, TR-267, TR-270, TR-275, TR-276, TR-279, TR-280, TR-281, TR-282, TR-284, TR-285, TR-286, TR-287, TR-288, TR-290, TR-292, TR-293, TR-301, TR-302, TR-304, TR-306, TR-308, TR-309, TR-315, TR-316, TR-317, TR-318, TR-319, TR-320, TR-321, TR-324, TR-325, TR-331, TR-332, TR-335, TR-3
  • the bivalent compound is not any of CPD-001 to CPD-246.
  • the bivalent compound is selected from the group consisting of CPD-247 to CPD-516, or a pharmaceutically acceptable salt or analog thereof.
  • the bivalent compound is selected from the group consisting of TR-247, TR-249, TR-250, TR-253, TR-254, TR-255, TR-258, TR-259, TR-260, TR-263, TR-264, TR-265, TR-266, TR-267, TR-268, TR-270, TR-275, TR-276, TR-279, TR-280, TR-281, TR-282, TR-284, TR-285, TR-286, TR-287, TR-288, TR-289, TR-290, TR-292, TR-293, TR-294, TR-301, TR-302, TR-303, TR-304, TR-305, TR-306, TR-308, TR-309, TR-315, TR-316, TR-317, TR-318, TR-319, TR-320, TR-321, TR-324, TR-325, TR-326, TR-327, TR-331, TR-332, TR-333, TR-335, TR-336, TR-337, TR-338, TR-339, TR-340, TR-341,
  • the bivalent compound comprises an enantiomer of a compound described herein. In some embodiments, the bivalent compound comprises an (S) enantiomer. In some embodiments, the bivalent compound comprises an (R) enantiomer. Some embodiments comprise a composition comprising the bivalent compound. In some embodiments, the composition comprises or consists of the (S) enantiomer of the compound. In some embodiments, the composition comprises or consists of the (R) enantiomer of the compound. In some embodiments, the composition comprises or consists of a mixture of the (S) enantiomer and the (R) enantiomer. In some embodiments, the composition comprises or consists of a racemic mixture of the (S) enantiomer and the (R) enantiomer. In some embodiments, the composition is a pharmaceutical composition.
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- ( (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) -2-oxoethyl) amino) isoindoline-1, 3-dione (TR-123) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) propyl) isoindoline-1, 3-dione (TR-172) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethoxy) isoindoline-1, 3-dione (TR-173) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- ( (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethyl) amino) isoindoline-1, 3-dione (TR-181) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (4- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) piperidin-1-yl) isoindoline-1, 3-dione (TR-182) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) azetidin-1-yl) isoindoline-1, 3-dione (TR-184) ;
  • the bivalent compound is 3- (6- (3- (4- (6- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) propyl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-185) .
  • the bivalent compound is 3- (5- (3- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) propyl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-186) .
  • the bivalent compound is 3- (5- ( (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethyl) amino) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-191) .
  • the bivalent compound is 3- (6- ( (2- (4- (6- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethyl) amino) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-196) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- ( (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) azetidin-1-yl) isoindoline-1, 3-dione (TR-198) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethyl) isoindoline-1, 3-dione (TR-204) .
  • the bivalent compound is 3- [5- [3- [4- [6- [6- [ (2R) -2- (3-fluorophenyl) pyrrolidin-1-yl] imidazo [1, 2-b] pyridazin-3-yl] -2-pyridyl] piperazin-1-yl] propylamino] -3-methyl-2-oxo-benzimidazol-1-yl] piperidine-2, 6-dione (TR-221) .
  • the bivalent compound is 3- ( (S) -5- (4- (3- (4- (6- (6- ( (S) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) prop-1-yn-1-yl) phenyl) -2-oxooxazolidin-3-yl) piperidine-2, 6-dione (TR-224) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- ( (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) pyrrolidin-1-yl) isoindoline-1, 3-dione (TR-225) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (4- ( (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) piperidin-1-yl) isoindoline-1, 3-dione (TR-226) .
  • the bivalent compound is N- [5- [ (3, 5-difluorophenyl) methyl] -1H-indazol-3-yl] -4- [4- [ [1- [2- (2, 6-dioxo-3-piperidyl) -1, 3-dioxo-isoindolin-5-yl] azetidin-3-yl] methyl] piperazin-1-yl] -2- (tetrahydropyran-4-ylamino) benzamide (TR-231) .
  • the bivalent compound is N- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) -2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) acetamide (TR-233) .
  • the bivalent compound is 3- (4- (4- (4- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) butyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (TR-241) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) methyl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-249) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) methyl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-254) .
  • the bivalent compound is 3- (4- (3- ( (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) azetidin- 1-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (TR-258) .
  • the bivalent compound is 3- (5- (4- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) butyl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (TR-259) .
  • the bivalent compound is 3- (5- (4- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) but-1-yn-1-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-1-yl) piperidine-2, 6-dione (TR-260) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (2- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) ethyl) piperazin-1-yl) benzamide (TR-263) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) glycyl) piperazin-1-yl) benzamide (TR-264) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) benzamide (TR-265) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) glycyl) piperazin-1-yl) -2- ( (2-fluoroethyl) amino) benzamide (TR-266) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (2-fluoroethyl) amino) benzamide (TR-267) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) pyrrolidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-270) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-275) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (3- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) propyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-276) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) methyl) piperidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-279) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) piperidin-4-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-280) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) methyl) piperidin-4-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-281) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) morpholin-2-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-282) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) pyrrolidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-284) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) methyl) pyrrolidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-285) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (2- ( (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) morpholino) isoindoline-1, 3-dione (TR-286) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- ( (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) oxy) azetidin-1-yl) isoindoline-1, 3-dione (TR-287) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (3- ( (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) amino) azetidin-1-yl) isoindoline-1, 3-dione (TR-288) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (6- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) -6-azaspiro [3.4] octan-2-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-290) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (1- (2- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) ethyl) azetidin-3-yl) isoindoline-1, 3-dione (TR-292) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (1- ( (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) methyl) azetidin-3-yl) isoindoline-1, 3-dione (TR-293) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) ethyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-301) .
  • the bivalent compound is 3- (5- (1- (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) azetidin-3-yl) -1-oxoisoindolin-2-yl)piperidine-2, 6-dione (TR-302) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (4- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-4-yl) butyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-304) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (4- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-4-yl) but-3-yn-1-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-306) .
  • the bivalent compound is 2- (2, 6-dioxopiperidin-3-yl) -5- (1- (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) azetidin-3-yl) isoindoline-1, 3-dione (TR-308) .
  • the bivalent compound is 3- (6- (1- (1- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperidin-4-yl) azetidin-3-yl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-309) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (3- ( (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-4-yl) amino) propyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-315) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (3- ( (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) amino) propyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-316) .
  • the bivalent compound is 3- (6- (3- ( (4- (6- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) methyl) azetidin-1-yl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-317) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -3-oxoisoindolin-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-318) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (4- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) but-3-yn-1-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-319) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (4- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) butyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-320) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-321) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (2- ( (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-5-yl) amino) ethyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-324) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (2- ( (1- (2, 6-dioxopiperidin-3-yl) -3-methyl-2-oxo-2, 3-dihydro-1H-benzo [d] imidazol-4-yl) amino) ethyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-325) .
  • the bivalent compound is 3- (5- (3- (4- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) azetidin-1-yl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-331) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-332) .
  • the bivalent compound is 3- (6- (3- (4- (6- (6- (6- ( (R) -2- (3-fluorophenyl) pyrrolidin-1-yl) imidazo [1, 2-b] pyridazin-3-yl) pyridin-2-yl) piperazin-1-yl) azetidin-1-yl) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione (TR-335) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -3-oxoisoindolin-5-yl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-336) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) amino) piperidin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-337) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (3- (2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) azetidin-1-yl) piperidin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-338) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (3- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-1-yl) piperidin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-339) .
  • the bivalent compound is N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (6- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) -2, 6-diazaspiro [3.3] heptan-2-yl) piperidin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-340) .
  • the bivalent compound is (S) -N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-341) .
  • the bivalent compound is (R) -N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) methyl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-342) .
  • the bivalent compound is (S) -N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-343) .
  • the bivalent compound is (R) -N- (5- (3, 5-difluorobenzyl) -1H-indazol-3-yl) -4- (4- (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) azetidin-3-yl) piperazin-1-yl) -2- ( (tetrahydro-2H-pyran-4-yl) amino) benzamide (TR-344) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) butanoyl) piperidin-4-yl) amino) picolinamide (CPD-470) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (6- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5- yl) amino) hexanoyl) piperidin-4-yl) amino) picolinamide (CPD-471) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (8- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) octanoyl) piperidin-4-yl) amino) picolinamide (CPD-472) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (3- (2- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) ethoxy) propanoyl) piperidin-4-yl) amino) picolinamide (CPD-473) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (3- (2- (2- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) ethoxy) ethoxy) propanoyl) piperidin-4-yl) amino) picolinamide (CPD-474) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (3- (2- (2- (2- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) ethoxy) ethoxy) ethoxy) propanoyl) piperidin-4-yl) amino) picolinamide (CPD-475) .
  • the bivalent compound is N- (5- ( (R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1, 5-a] pyrimidin-3-yl) -6- ( (1- (1- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) amino) -3, 6, 9, 12-tetraoxapentadecan-15-oyl) piperidin-4-yl) amino) picolinamide (CPD-476) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) glycyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-478) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) butanoyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-480) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- (5- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) pentanoyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-481) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- (6- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) hexanoyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-482) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- (7- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) heptanoyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-483) .
  • the bivalent compound is N- (2- (4-carbamoylpiperidin-1-yl) -4- ( (4- (8- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) octanoyl) piperazin-1-yl) methyl) phenyl) -2-morpholinooxazole-4-carboxamide (CPD-484) .
  • the bivalent compound is 2- (4- (2-amino-3- (3-methoxy-4- ( (4-methoxybenzyl) oxy) benzyl) -3H-imidazo [4, 5-b] pyridin-6-yl) -1H-pyrazol-1-yl) -N- (4- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) butyl) acetamide (CPD-499) .
  • the bivalent compound is 2- (4- (2-amino-3- (3-methoxy-4- ( (4- methoxybenzyl) oxy) benzyl) -3H-imidazo [4, 5-b] pyridin-6-yl) -1H-pyrazol-1-yl) -N- (6- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) hexyl) acetamide (CPD-500) .
  • the bivalent compound is 2- (4- (2-amino-3- (3-methoxy-4- ( (4-methoxybenzyl) oxy) benzyl) -3H-imidazo [4, 5-b] pyridin-6-yl) -1H-pyrazol-1-yl) -N- (8- ( (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) amino) octyl) acetamide (CPD-501) .
  • composition disclosed herein comprises the bivalent compound or a pharmaceutically acceptable salt or analog thereof, and a pharmaceutically acceptable carrier or diluent.
  • a method of treating a tropomyosin receptor kinase (TRK) -mediated disease disclosed herein comprises administering to a subject with a TRK-mediated disease the bivalent compound or a pharmaceutically acceptable salt or analog thereof.
  • TRK tropomyosin receptor kinase
  • the TRK-mediated disease results from TRK expression, mutation, or fusion.
  • the subject with the TRK-mediated disease has an elevated TRK function relative to a healthy subject without the TRK-mediated disease.
  • the bivalent compound is selected from the group consisting of CPD-001 to CPD-516, or analogs thereof.
  • the bivalent compound is selected from the group consisting of CPD-247 to CPD-516, or analogs thereof.
  • the bivalent compound is administered to the subject orally, parenterally, intradermally, subcutaneously, topically, or rectally. In one embodiment, the method further comprises administering to the subject an additional therapeutic regimen for treating cancer.
  • the additional therapeutic regimen is selected from the group consisting of surgery, chemotherapy, radiation therapy, hormone therapy, and immunotherapy.
  • the TRK-mediated disease is selected from the group consisting of non-small cell lung cancer, colorectal cancer, gastric cancer, liver cancer, invasive breast cancer, lung adenocarcinoma, uterine cancer, adrenal cancer, pancreatic cancer, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, prostate cancer low-grade glioma, glioblastoma, Spitzoid cancer, soft tissue sarcoma, papillary thyroid carcinoma, head and neck squamous cell carcinoma, congenital fibrosarcoma, congenital mesoblastic nephroma, secretory breast carcinoma, mammary analogue secretory carcinoma, acute myeloid leukemia, ductal carcinoma, pulmonary neuroendocrine tumors, pheochromocytoma, and Wilms' tumor.
  • the TRK-mediated disease or condition comprises cancer, inflammatory diseases, acute and chronic pain, pruritus, bone-related diseases, neurodegenerative diseases, infectious diseases, and other diseases, including but not limited to neuroblastoma, prostate cancer, pancreatic cancer, melanoma, head and neck cancer, gastric carcinoma, lung carcinoma, liver cancer, uterine cancer, adrenal cancer, biliary tree cancer, intestinal cancer, colorectal cancer, ovarian cancer, lung carcinoma, small cell lung cancer, non-small cell lung cancer, gastric carcinoma, breast cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, brain cancer, low-grade glioma, glioblastoma, medulloblastoma, secratory breast cancer, secretory breast carcinoma, salivary gland cancer, papillary thyroid carcinoma, ductal carcinoma, adult myeloid leukemia, acute myeloid leukemia, large cell neuroendocrine tumors , pulmonary neuroendocrine tumors, sarcomas
  • lymphoma including Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma
  • inflammatory lung diseases e.g. asthma
  • inflammatory bowel diseases e.g. ulcerative colitis, Crohn's disease
  • inflammatory skin diseases e.g.
  • interstitial cystitis atopic dermatitis, eczema and psoriasis
  • interstitial cystitis rhinitis, acute pain, chronic pain, cancer pain, surgical pain, inflammatory pain, neuropathic pain, nociceptive pain, pain of osteoarthritis, chronic low back pain, low back pain of osteoporosis, pain of bone fracture, pain of rheumatoid arthritis, postherpetic pain, pain of diabetic neuropathy, fibromyalgia, pain of pancreatitis, pain of interstitial cystitis, pain of endometriosis, pain of irritable bowel syndrome, migraine, pain of pulpitis, interstitial cystitis pain, painful bladder syndrome, central pain syndromes, postsurgical pain syndromes, bone and joint pain, repetitive motion pain, dental pain, myofascial pain, perioperative pain, dysmennorhea, myofascial pain, angina pain, headache, primary hyperalgesia, secondary hyperalgesia,
  • the TRK-mediated disease is a relapsed cancer.
  • the TRK-mediated disease is refractory to one or more previous treatments.
  • a method for identifying a bivalent compound which mediates degradation or reduction of TRK comprises:
  • heterobifunctional test compound comprising an TRK ligand conjugated to a degradation tag through a linker
  • heterobifunctional test compound as a bivalent compound which mediates degradation or reduction of TRK.
  • the cell is a cancer cell.
  • the cancer cell is a TRK-mediated cancer cell.
  • the cell is a neuron.
  • FIG. 1A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with Entrectinib or bivalent compounds CPD-001 –CPD-022.
  • FIG. 1B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with Entrectinib or bivalent compounds CPD-023 –CPD-044.
  • FIG. 1C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with Entrectinib or bivalent compounds CPD-045 –CPD-065.
  • FIG. 2 shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with Entrectinib or bivalent compounds CPD-027, CPD-053, and CPD-060 at various time points.
  • FIG. 3 shows immunoblots of TPM3-TRKA fusion protein expressed by KM12 cells in subcutaneous xenograft tumors after treatment with a dose range of CPD-027, CPD-053, and CPD-060.
  • FIG. 4A shows a graph of KM12 cell viability vs. concentration of bivalent compounds CPD-010, CPD-053, and CPD-057.
  • FIG. 4B shows KM12 and H358 cell viability vs. concentration of bivalent compound CPD-053.
  • FIG. 5A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with GNF-8625, LOXO101 or bivalent compounds TR-104 –TR-129.
  • FIG. 5B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-115, TR-116, TR-119, TR-123, TR-124, TR-127 or TR-129.
  • FIG. 5C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-130, TR-131, TR-132, TR-140, TR-146, TR-150 or TR-168.
  • FIG. 6A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-171, TR-172, TR-173 or TR-176.
  • FIG. 6B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-177, TR-181, TR-182 or GNF-8625.
  • FIG. 6C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-186, TR-188, TR-189 or TR-190.
  • FIG. 6D shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-191, TR-194, TR-196, TR198 or GNF-8625.
  • FIG. 7 shows immunoblots of overexpressed TPM3-TRKA, AGBL4-TRKB and ETV6-TRKC fusion protein in KM12 cells after treatment with a dose range of TR-123.
  • FIG. 8A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of compound TR-123 or TR-123-neg.
  • FIG. 8B shows an immunoblot of wild type TRKA protein expressed by HEL cells after treatment with a dose range of compound TR-123 or TR-123-neg.
  • FIG. 9A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a single dose of TR-123 or combinations with MG-132, Bortezomib or MLN4924.
  • FIG. 9B shows an immunoblot of wild type TRKA protein expressed by HEL cells after treatment with a single dose of TR-123 or combinations with MG-132, Bortezomib, MLN4924 or Pomalidomide.
  • FIG. 10A shows an immunoblot of TPM3-TRKA fusion protein in subcutaneous KM12 xenograft tumors after treatment with a dose range of TR-123.
  • FIG. 10B shows an immunoblot of TPM3-TRKA fusion protein expressed in subcutaneous KM12 xenograft tumors after treatment with TR-171, TR-172, TR-173, TR-177 or TR-181.
  • FIG. 11 shows a graph of plasma concentration of TR-123 vs. time points post dosing.
  • FIG. 12A shows a graph of subcutaneous KM12 xenograft tumor volume vs. days after treatment with a dose range of CPD-060.
  • FIG. 12B shows a graph of body weight vs. days after treatment with a dose range of CPD-060.
  • FIG. 13A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-202, TR-203 or TR-204.
  • FIG. 13B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-208, TR-210, TR-211 or TR-214.
  • FIG. 13C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-215, TR216, TR-217, TR218, TR-219 or TR-220.
  • FIG. 13D shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-221, TR-222, TR-223, TR-224, TR-225, TR-226 or TR-227.
  • FIG. 13E shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-231, TR-232, TR-233, TR-234 or TR-235.
  • FIG. 14 shows a graph of plasma concentration of TR-198 over time after dosing via intravenous injection or oral gavage.
  • FIG. 15A shows a graph of subcutaneous KM12 xenograft tumor volume as a function of days after treatment with a dose range of TR-181 or a single dose of TR-198.
  • FIG. 15B shows a graph of body weight as a functional of days after treatment with a dose range of TR-181 or a single dose of TR-198.
  • FIG. 16A shows a graph of the percentage of weight born on the injured limb following treatment with a single dose of vehicle (Veh) , TR-181 or ibuprofen (Ibu) in rats.
  • FIG. 16B shows a graph of the percentage of weight born on the injured limb following treatment with a single dose of TR-181 or ibuprofen (Ibu) in guinea pigs.
  • FIG. 17A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-247, TR-248, TR-249, TR-250, TR-251, TR-252, or TR-253.
  • FIG. 17B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-254, TR-255, TR-256, TR-257, TR-258, TR-259, or TR-260.
  • FIG. 17C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-261, TR-262, TR-263, TR-264, TR-265, TR-256, or TR-267.
  • FIG. 18A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-268, TR-269, Tr-270, TR-271, or TR-272.
  • FIG. 18B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-273, TR-274, TR-275, TR-276, or TR-277.
  • FIG. 18C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-279, Tr-280, TR-281, TR-282, or TR-283.
  • FIG. 19A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-284, TR-285, TR-286, TR-287, or TR-288.
  • FIG. 19B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-289, TR-290, TR-291, TR-292, TR-293, or TR-294.
  • FIG. 19C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-295, TR-296, TR-297, TR-298, TR-300, or TR-301.
  • FIG. 20A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-302, TR-303, TR-304, TR-305, TR-306, or TR-307.
  • FIG. 20B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-308, TR-309, TR-310. TR-311, TR-312, or TR-313.
  • FIG. 20C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-314, TR-315, TR-316, TR-317, TR-318, TR-319, or TR-320.
  • FIG. 21A shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-321, TR-322, TR-323, TR-324, TR-325, TR-326, or TR-327.
  • FIG. 21B shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-328, TR-329, TR-330, TR-331, TR-332, TR-333, or TR-334.
  • FIG. 21C shows an immunoblot of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with a dose range of TR-335, TR-336, TR-337, TR-338, TR-339, or TR-340.
  • FIG. 22 shows an immunoblot of NPM-ALK fusion protein expressed in SU-DHL-1 cells after treatment with a dose range of entrectinib, CPD-032, CPD-037, or CPD-055.
  • FIG. 23A shows graphs of plasma concentrations of TR-231 and TR-275 over time after dosing via intravenous injection or oral gavage.
  • FIG. 23B shows an immunoblot of TPM3-TRKA fusion protein expressed in subcutaneous KM12 xenograft tumors after treatment with TR-231 and TR-275 at different oral doses and at different time points.
  • FIG. 24A shows KM12 xenograft tumor growth curves in mice treated with vehicle or 40 mg/kg TR-231 twice per day.
  • FIG. 24B shows KM12 xenograft tumor growth curves in mice treated with vehicle or 40 mg/kg TR-275 twice per day.
  • FIG. 25A-25C shows immunoblots of TPM3-TRKA fusion protein expressed by KM12 cells after treatment with heterobifunctional compounds.
  • FIG. 26 shows an immunoblot of wildtype TRKA protein expressed by HEL cells after treatment with heterobifunctional compounds.
  • FIG. 27A-27C shows graphs of KM12 cell viability vs. concentration of heterobifunctional compounds CPD-470, CPD-471, CPD-474, CPD-480, CPD-481, CPD-482, CPD-499, CPD-500, and CPD-501.
  • FIG. 28A-28B show immunoblots of TPM3-TRKA fusion protein expressed in a cell line after treatment with heterobifunctional compounds.
  • TRK tropomyosin receptor kinase
  • TRKA tropomyosin receptor kinase
  • TRKB TRKC that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively
  • NTRKs are receptor tyrosine kinases primarily implicated in development and functions of the neuronal tissues.
  • the main ligands of TRKs include nerve growth factor (NGF) for TRKA, brain-derived growth factor (BDGF) for TRKB, and neurotrophins for TRKC (Vaishnavi et al., 2015) .
  • NGF nerve growth factor
  • BDGF brain-derived growth factor
  • TRKC neurotrophins for TRKC
  • TRKs are aberrantly activated in a variety of human malignancies.
  • the primary molecular mechanism activating TRKs in cancer is not point mutations but in-frame fusions of NTRK genes (Vaishnavi et al., 2015) .
  • the 3’ regions of the NTRK genes are joined with the 5’ regions of a partner gene due to chromosomal rearrangement.
  • the resulted chimeric proteins always retain the kinase domain of TRK proteins, indicating that the catalytic functions are crucial to the transforming activities.
  • TRK fusions Loss of the 5’ regions of the NTRK genes that encode the self-inhibitory domains renders these fusion kinases constitutively active. Additionally, expression of the chimeric proteins is driven by the promoters of the fusion partners, which often result in overexpression.
  • the most common TRK fusions include LMNA-TRKA, TPM3-TRKA, and ETV6-TRKC (Amatu et al., 2016) . Hence, genetic events lead to overexpressed and constitutively active TRK-fusion kinases. These fusions are oncogenic, as shown by their ability to transform mouse embryonic fibroblasts and normal epithelium (Russell et al., 2000; Vaishnavi et al., 2015) .
  • TRK fusion was first reported in a human colon carcinoma, which was named as oncD at that time (Martin-Zanca et al., 1986) . Recent advances in high-throughput RNA sequencing greatly promote the efficiency of identifying chromosomal rearrangement events in patient samples.
  • TRK fusions have been found across a wide range of human malignancies, including but are not limited to non-small cell lung cancer, colorectal cancer, gastric cancer, low-grade glioma glioblastoma, Spitzoid cancer, soft tissue sarcoma, papillary thyroid carcinoma, head and neck squamous cell carcinoma, congenital fibrosarcoma, congenital mesoblastic nephroma, secretory breast carcinoma, mammary analogue secretory carcinoma, acute myeloid leukemia, and ductal carcinoma (Amatu et al., 2016; Khotskaya et al., 2017) .
  • the frequency of TRK fusions is relatively low.
  • TRK fusions For example, approximately 0.5%to 2.7%colon cancers are affected by TRK fusions (Creancier et al., 2015; Lee et al., 2015) . However, for certain cancer types, such as secretory breast carcinoma, TRK fusions can be found in the vast majority of cases (Tognon et al., 2002) .
  • TRK mutations and deletions have been observed in additional human diseases, such as pulmonary neuroendocrine tumors, anhidrosis syndrome, obesity, congenital heart defects, and acute myeloid leukemia (Khotskaya et al., 2017) .
  • TRK amplification are associated with several human diseases, such as liver cancer, invasive breast cancer, lung adenocarcinoma, uterine cancer, adrenal cancer, pancreatic cancer, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, pheochromocytoma, Wilms' tumor, and prostate cancer (Khotskaya et al., 2017) .
  • NGF The never growth factor
  • TRKA tropomyosin receptor kinase A
  • Nociceptive neurons express TRKA and mediate pain sensation by transmitting pain signals to the central nervous system.
  • Multiple NGF-neutralizing antibodies, such as tanezumab, are undergoing clinical assessment in patients with osteoarthritis, lower back pain, cancer pain, neuropathic pain, and other pain conditions (Miller et al., 2017) .
  • the efficacy of NGF antibodies in pain relief has been clearly documented in clinics.
  • NGF neutralizing antibodies have been shown to result in rapidly progressed joint destruction in some patients that leads to total joint replacement (Schnitzer and Marks, 2015) . These adverse events may be related to sustained exposure to NGF antibodies.
  • Targeting TRK represents another promising therapeutic strategy blocking the NGF/TRK signaling pathway for pain management.
  • pan-TRK kinase inhibitors may induce significant on-target adverse effects through modulating TRK family members in the central nervous system.
  • Peripherally restricted TRK bifunctional degraders are expected to selective block the NGF/TRK pathway in peripheral nerves while spare these targets in the central nervous system.
  • TRK is associated with cancer, inflammatory diseases, acute and chronic pain, pruritus, bone-related diseases, neurodegenerative diseases, infectious diseases, and other diseases, including but no limited to neuroblastoma, prostate cancer, pancreatic cancer, melanoma, head and neck cancer, gastric carcinoma, lung carcinoma, liver cancer, uterine cancer, adrenal cancer, biliary tree cancer, intestinal cancer, colorectal cancer, ovarian cancer, lung carcinoma, small cell lung cancer, non-small cell lung cancer, gastric carcinoma, breast cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, brain cancer, low-grade glioma, glioblastoma, medulloblastoma, secretory breast carcinoma, salivary gland cancer, papillary thyroid carcinoma, ductal carcinoma, acute myeloid leukemia, large cell neuroendocrine tumors, pulmonary neuroendocrine tumors, sarcomas, pheochromocytoma, fibrosarcoma, congenital fibro
  • lymphoma including Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma
  • inflammatory lung diseases e.g. asthma
  • inflammatory bowel diseases e.g. ulcerative colitis, Crohn's disease
  • inflammatory skin diseases e.g.
  • interstitial cystitis atopic dermatitis, eczema and psoriasis
  • interstitial cystitis rhinitis, acute pain, chronic pain, cancer pain, surgical pain, inflammatory pain, neuropathic pain, nociceptive pain, pain of osteoarthritis, chronic low back pain, low back pain of osteoporosis, pain of bone fracture, pain of rheumatoid arthritis, postherpetic pain, pain of diabetic neuropathy, fibromyalgia, pain of pancreatitis, pain of interstitial cystitis, pain of endometriosis, pain of irritable bowel syndrome, migraine, pain of pulpitis, interstitial cystitis pain, painful bladder syndrome, central pain syndromes, postsurgical pain syndromes, bone and joint pain, repetitive motion pain, dental pain, myofascial pain, perioperative pain, dysmennorhea, myofascial pain, angina pain, headache, primary hyperalgesia, secondary hyperalgesia,
  • TRK kinase inhibitors are currently undergoing clinical or pre-clinical development, including but are not limited to entrectinib (RXDX-101) (Menichincheri et al., 2016) , GNF-8625 (Choi et al., 2015) , larotrectinib (LOXO-101; ARRY-470) (Drilon et al., 2018) , altiratinib (DCC2701, DCC-270, DP-5164) (Smith et al., 2015) , sitravatinib (MGCD516) (Patwardhan et al., 2016) , cabozantinib (XL-184, BMS-907351) (Fuse et al., 2017) , dovitinib (TKI-258, CHIR-258) (Chong et al., 2017) , milciclib (PHA-848125AC) (Brasca et al., 2009) , bel
  • phase 2 results of larotrectinib demonstrated that most patients (75%) responded to the therapy and that 55%patient remained progression-free at 1 year (Drilon et al., 2018) .
  • Phase 1 results of entrectinib also recorded marked and durable response in patients with TRK-fusion tumors (Drilon et al., 2017b) .
  • the remarkable efficacy of TRK inhibitors was independent of tumor types.
  • TRK kinase inhibitors Non-specific side effects and the development of resistance to TRK kinase inhibitors remain a challenge in development of effective treatments. Thus, new small-molecule targeting TRK’s functions through inhibition and/or degradation will be very useful.
  • TRK-mediated diseases particularly non-small cell lung cancer, colorectal cancer, gastric cancer, liver cancer, invasive breast cancer, lung adenocarcinoma, uterine cancer, adrenal cancer, pancreatic cancer, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, prostate cancer, low-grade glioma, glioblastoma, Spitzoid cancers, soft tissue sarcoma, papillary thyroid carcinoma, head and neck squamous cell carcinoma, congenital fibrosarcoma, congenital mesoblastic nephroma, secretory breast carcinoma, mammary analogue secretory carcinoma, acute myeloid leukemia, ductal carcinoma,
  • the disclosed noval bifunctional TRK degraders are useful in the treatment of TRK-mediated cancer, inflammatory diseases, acute and chronic pain, pruritus, bone-related diseases, neurodegenerative diseases, infectious diseases, and other diseases, including but not limited to neuroblastoma, prostate cancer, pancreatic cancer, melanoma, head and neck cancer, gastric carcinoma, lung carcinoma, liver cancer, uterine cancer, adrenal cancer, biliary tree cancer, intestinal cancer, colorectal cancer, ovarian cancer, lung carcinoma, small cell lung cancer, non-small cell lung cancer, gastric carcinoma, breast cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, brain cancer, low-grade glioma, glioblastoma, medulloblastoma, secratory breast cancer, secretory breast carcinoma, salivary gland cancer, papillary thyroid carcinoma, ductal carcinoma, adult myeloid leukemia, acute myeloid leukemia, large cell neuroendocrine tumors , pulmonary neuroendocrine tumor
  • lymphoma including Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma
  • inflammatory lung diseases e.g. asthma
  • inflammatory bowel diseases e.g. ulcerative colitis, Crohn's disease
  • inflammatory skin diseases e.g.
  • interstitial cystitis atopic dermatitis, eczema and psoriasis
  • interstitial cystitis rhinitis, acute pain, chronic pain, cancer pain, surgical pain, inflammatory pain, neuropathic pain, nociceptive pain, pain of osteoarthritis, chronic low back pain, low back pain of osteoporosis, pain of bone fracture, pain of rheumatoid arthritis, postherpetic pain, pain of diabetic neuropathy, fibromyalgia, pain of pancreatitis, pain of interstitial cystitis, pain of endometriosis, pain of irritable bowel syndrome, migraine, pain of pulpitis, interstitial cystitis pain, painful bladder syndrome, central pain syndromes, postsurgical pain syndromes, bone and joint pain, repetitive motion pain, dental pain, myofascial pain, perioperative pain, dysmennorhea, myofascial pain, angina pain, headache, primary hyperalgesia, secondary hyperalgesia,
  • Selective degradation of a target protein induced by a small molecule may be achieved by recruiting an E3 ubiquitin ligase and mimicking protein misfolding with a hydrophobic tag (Buckley and Crews, 2014) . Additionally, the small molecule has one moiety that binds to an E3 ubiquitin ligase and another moiety that binds the protein target of interest (Buckley and Crews, 2014) . The induced proximity leads to ubiquitination of the target followed by its degradation via proteasome-mediated proteolysis.
  • E3 ligase ligands have been identified or developed.
  • immunomodulatory drugs such as thalidomide and pomalidomide, which bind cereblon (CRBN or CRL4CRBN) , a component of a cullin-RING ubiquitin ligase (CRL) complex
  • IMDs immunomodulatory drugs
  • thalidomide and pomalidomide which bind cereblon
  • CRL cullin-RING ubiquitin ligase
  • VHL-1 a hydroxyproline-containing ligand, which binds van Hippel-Lindau protein
  • VHL or CRL2VHL van Hippel-Lindau protein
  • the E3 ligase recruiting bifunctional degrader technology has been applied to degradation of several protein targets (Bondeson et al., 2015; Buckley et al., 2015; Lai et al., 2016; Lu et al., 2015; Winter et al., 2015; Zengerle et al., 2015) .
  • a hydrophobic tagging approach which utilizes a bulky and hydrophobic adamantyl group, has been developed to mimic protein misfolding, leading to the degradation of the target protein by proteasome (Buckley and Crews, 2014) .
  • This approach has been applied to selective degradation of the pseudokinase HER3 (Xie et al., 2014) .
  • the inventors have not yet seen any efforts applying any of these approaches to degradation of TRK, TRK mutant, TRK deletion, TRK splicing or TRK fusion proteins.
  • TRK kinase inhibitors such as entrectinib (RXDX-101) (Menichincheri et al., 2016) , GNF-8625 (Choi et al., 2015) , larotrectinib (LOXO-101; ARRY-470) (Drilon et al., 2018) , altiratinib (DCC2701, DCC-270, DP-5164) (Smith et al., 2015) , sitravatinib (MGCD516) (Patwardhan et al., 2016) , cabozantinib (XL-184, BMS-907351) (Fuse et al., 2017) , dovitinib (TKI-258, CHIR-258) (Chong et al., 2017) , milciclib (PHA-848125AC) (Bra
  • a novel approach is taken: to develop compounds that directly and selectively modulate not only the kinase activity of TRK, but also its protein level.
  • Strategies for inducing protein degradation include recruiting E3 ubiquitin ligases, mimicking protein misfolding with hydrophobic tags, and inhibiting chaperones.
  • Such an approach based on the use of bivalent small molecule compounds, permits more flexible regulation of protein levels in vitro and in vivo compared with techniques such as gene knockout or short hairpin RNA-mediated (shRNA) knockdown.
  • shRNA short hairpin RNA-mediated
  • a small molecule approach further provides an opportunity to study dose and time dependency in a disease model through modulating the administration routes, concentrations and frequencies of administration of the corresponding small molecule.
  • bifunctional compound for the purpose of the present disclosure, the terms “bifunctional compound” , “bifunctional degrader” , “bifunctional TRK degrader” , “bivalent compound” and “heterobifunctional compound” are used interchangeably.
  • the present disclosure provides bivalent compounds including a TRK ligand conjugated to a degradation tag, or a pharmaceutically acceptable salt or analog thereof.
  • the TRK ligand may be conjugated to the degradation tag directly or via a linker moiety.
  • the TRK ligand may be conjugated to the degradation tag directly.
  • the TRK ligand may be conjugated to the degradation tag via a linker moiety.
  • the terms “tropomyosin receptor kinase ligand” and “TRK ligand” , or “TRK targeting moiety” are to be construed to encompass any molecules ranging from small molecules to large proteins that associate with or bind to TRK protein.
  • the TRK ligand is capable of binding to a TRK protein comprising TRK, a TRK mutant, a TRK deletion, a TRK splicing, or a TRK fusion protein.
  • the TRK ligand can be, for example but not limited to, a small molecule compound (i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa) ) , a peptide or polypeptide, nucleic acid or oligonucleotide, carbohydrate such as oligosaccharides, or an antibody or fragment thereof.
  • a small molecule compound i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa)
  • a peptide or polypeptide i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa)
  • a peptide or polypeptide i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa)
  • a peptide or polypeptide i.e., a molecule of molecular weight less than about 1.5
  • the TRK ligand or targeting moiety can be a TRK kinase inhibitor or a portion of TRK kinase inhibitor.
  • the TRK kinase inhibitor comprises one or more of (e.g., entrectinib (RXDX-101) (Menichincheri et al., 2016) , GNF-8625 (Choi et al., 2015) , larotrectinib (LOXO-101; ARRY-470) (Drilon et al., 2018) , altiratinib (DCC2701, DCC-270, DP-5164) (Smith et al., 2015) , sitravatinib (MGCD516) (Patwardhan et al., 2016) , cabozantinib (XL-184, BMS-907351) (Fuse et al., 2017) , dovitinib (TKI-258, CHIR-258) (Chong et al.
  • TRK kinase inhibitor refers to an agent that restrains, retards, or otherwise causes inhibition of a physiological, chemical or enzymatic action or function and causes a decrease in binding of at least 5%.
  • An inhibitor can also or alternately refer to a drug, compound, or agent that prevents or reduces the expression, transcription, or translation of a gene or protein.
  • An inhibitor can reduce or prevent the function of a protein, e.g., by binding to or activating/inactivating another protein or receptor.
  • the TRK ligand is derived from a TRK kinase inhibitor comprising:
  • the TRK ligand include, but are not limited to DS-6051b (Fujiwara et al., 2018) , F17752 (Amatu et al., 2016) , PLX7486 (Amatu et al., 2016) , AZD-6918 (Li et al., 2015) , ASP7962 (Bailey et al., 2017a, b) , VM902A (Bailey et al., 2017a, b) , PF-06273340 (Skerratt et al., 2016) and ONO-4474 (Bailey et al., 2017a, b) .
  • the TRK ligand is derived from any one or more of DS-6051b (Fujiwara et al., 2018) , F17752 (Amatu et al., 2016) , PLX7486 (Amatu et al., 2016) , AZD-6918 (Li et al., 2015) , ASP7962 (Bailey et al., 2017a, b) , VM902A (Bailey et al., 2017a, b) , PF-06273340 (Skerratt et al., 2016) and ONO-4474 (Bailey et al., 2017a, b) .
  • X 1 and X 2 are independently selected from CH and N;
  • X 3 and X 4 are independently selected from C (O) and CR 4 R 5 ;
  • R 1 is selected from H, -NR 2 R 3 , halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy;
  • R 2 , R 3 , R 4 , and R 5 are independently selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy; and
  • L is selected from a bond
  • one of X 3 and X 4 is C (O) and the other is CR 4 R 5 ;
  • X 1 and X 2 are each N.
  • X 3 is C (O) and X 4 is CR 4 R 5 . In some embodiments, X 3 is C (O) and X 4 is CR 4 R 5 .
  • X 3 and X 4 are both C (O) . In some embodiments, X 3 and X 4 are both CR 4 R 5 .
  • R 1 is -NR 2 R 3 . In some embodiments, R 1 is
  • X 1 and X 2 are independently selected from CH and N;
  • X 3 and X 4 are independently selected from C (O) , CR 4 R 5 , and NR 6 ;
  • R 1 is selected from H, -NR 2 R 3 , halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted aryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy;
  • R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 7 ) R”, R’C (S) N (R 7 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 7 ) R”, R’N (R 7 ) R”, R”N (R 7 ) COR”, R’N (R 7 ) CON (R 8 ) R”, R’N (R 7 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 3 or X 4 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 7 and R 8 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • L is selected from
  • X 1 and X 2 are each N.
  • At least one of X 3 and X 4 is NR 6 . In some embodiments, X 3 and X 4 are both NR 6 .
  • either X 3 or X 4 is -N- (2, 6-dioxopiperidin-3-yl) .
  • R 1 is -NR 2 R 3 . In some embodiments, R 1 is
  • L is connected to X 3 . In some embodiments, L is connected to X 4 .
  • X 1 and X 2 are independently selected from CH and N;
  • one of X 3 and X 4 is C (O) and the other is CR 1 R 2 ;
  • X 3 and X 4 are each C (O) ;
  • R 1 and R 2 are independently selected from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, and optionally substituted C 1-6 alkoxy.
  • X 1 and X 2 are each N.
  • X 1 and X 3 are independently selected from CR 1 , CR 1 R 2 , O, N, and NR 1 ;
  • X 2 is selected from N, CO, and CH;
  • Y is selected from O, NR 8 and CR 8 R 9 ;
  • Ar is selected from C 6-10 aryl and 5-to 10-membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from hydrogen, halogen, CN, NO 2 , OR 17 , SR 17 , NR 18 R 19 , COR 17 , CO 2 R 17 , CONR 18 R 19 , SOR 17 , SO 2 R 17 , SO 2 NR 18 R 19 , NR 17 COR 19 , NR 17 C (O) NR 18 R 19 , NR 18 SOR 17 , NR 18 SO 2 R 17 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 1-8 alkyl amino, optionally substituted C 3-10 carbocyclyl, -O-
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 21 ) R”, R’C (S) N (R 21 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 21 ) R”, R’N (R 21 ) R”, R”N (R 21 ) COR”, R’N (R 21 ) CON (R 22 ) R”, R’N (R 21 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 1 or X 3 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 1 and R 2 are independently selected at each occurrence from H, halogen, optionally substituted C 1- 6 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1- 6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • R 3 is selected from a bond, -OR 14 -, -SR 14 -, -N (R 15 ) R 14 -, -COR 14 -, -CO 2 R 14 -, -CON (R 15 ) R 14 -, -SOR 14 -, -SO 2 R 14 -, -SO 2 N (R 15 ) R 14 -, -N (R 16 ) COR 14 -, -N (R 16 ) CON (R 15 ) R 14 -, N (R 16 ) SOR 14 -, -N (R 16 ) SO 2 R 14 -, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl
  • R 4 , R 5 , and R 6 are independently selected from hydrogen, halogen, CN, NO 2 , OR 10 , SR 11 , NR 12 R 13 , COR 10 , CO 2 R 10 , C (O) NR 12 R 13 , SOR 10 , SO 2 R 10 , SO 2 NR 12 R 13 , NR 10 C (O) R 13 , NR 10 C (O) NR 12 R 13 , NR 10 SOR 13 , NR 10 SO 2 R 13 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1- 8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, and optionally substituted 3-to 10-membered heterocyclyl;
  • R 7 is selected from optionally substituted C 1-8 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 8 and R 9 are independently selected from hydrogen, halogen, OH, optionally substituted C 1-8 alkyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , and optionally substituted 3-to 10-membered heterocyclyl; or
  • R 8 and R 9 are taken together with the atom to which they are connected to form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 10 , R 11 , R 12 , and R 13 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 12 and R 13 are taken together with the atom to which they are connected to form an optionally substituted 3-to 10-membered heterocyclyl;
  • R 14 is selected from null, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 15 and R 16 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 14 and R 15 together with the atom to which they are connected, optionally form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 17 , R 18 , and R 19 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 18 and R 19 are together with the atom to which they are connected to form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 21 and R 22 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring.
  • L is selected from
  • R 4 , R 5 , and R 6 are each hydrogen.
  • Y is CR 8 R 9 . In some embodiments, Y is CH 2 .
  • R 7 is optionally substituted C 6-10 aryl. In some embodiments, R 7 is
  • Ar is C 6-10 aryl substituted with NR 18 R 19 . In some embodiments, Ar is
  • R 3 is optionally substituted 3-to 10-membered heterocyclyl. In some embodiments, R 3 is
  • X 1 is CR 1 , X 2 is CH, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is CR 1 .
  • X 1 is CR 1 , X 2 is N, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is N, and X 3 is CR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is N.
  • X 1 is N, X 2 is CH, and X 3 is NR 1 .
  • X 1 is CR 1 R 2 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is O, X 2 is CO, and X 3 is NR 1 .
  • X 1 is CR 1 , X 2 is CO, and X 3 is NR 1 .
  • X 1 is N, X 2 is CO, and X 3 is NR 1 .
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • X 1 and X 3 are independently selected from CR 1 , N, and NR 1 ;
  • X 2 is selected from N and CH;
  • Y 1 is selected from N and CR 6 ;
  • Y 2 , Y 3 , and Y 4 are independently selected from N and C, with the proviso that only one of Y 2 , Y 3 , and Y 4 is N;
  • Z is selected from null, a bond, C (R 5 ) 2 , C (R 5 ) 2 C (R 5 ) 2 , CO, C (R 5 ) 2 CO, CONR 5 , C (R 5 ) 2 O, C (R 5 ) 2 NR 5 and CH 2 NR 5 ;
  • Ar 1 and Ar 2 are independently selected from C 6-10 aryl and 5-to 10-membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from halogen, CN, NO 2 , OR 10 , SR 10 , NR 11 R 12 , COR 10 , CO 2 R 10 , CONR 11 R 12 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 , NR 10 COR 12 , NR 10 C (O) NR 11 R 12 , NR 10 SOR 12 , NR 10 SO 2 R 12 , optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2-8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 haloalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optional
  • L is selected from a bond, R’-R”, R’COR”, R’CO 2 R”, R’C (O) N (R 13 ) R”, R’C (S) N (R 13 ) R”, R’OR”, R’SR”, R’SOR”, R’SO 2 R”, R’SO 2 N (R 13 ) R”, R’N (R 13 ) R”, R”N (R 13 ) COR”, R’N (R 13 ) CON (R 14 ) R”, R’N (R 13 ) C (S) R”, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 al
  • L is optionally attached to X 1 or X 3 ;
  • R’ and R” are independently selected from null, optionally substituted C 1 -C 8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 1 -C 8 hydroxyalkylene, optionally substituted C 1 -C 8 aminoalkylene, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkylene, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkylene, optionally substituted C 1 -C 8 haloalkylene, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 4 -C 13 fused carbocyclyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted C 5 -
  • R 1 is selected at each occurrence from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted 5-to 10-membered heteroaryl, optionally substituted C 1- 6 heteroalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 alkoxy, and optionally substituted 2, 6-dioxopiperidin-3-yl;
  • R 3 is selected from a bond, -OR 7 -, -SR 7 -, -N (R 8 ) R 7 -, -COR 7 -, -CO 2 R 7 -, -CON (R 8 ) R 7 -, -SOR 7 -, -SO 2 R 7 -, -SO 2 N (R 8 ) R 7 -, -N (R 9 ) COR 7 -, -N (R 9 ) CON (R 8 ) R 7 -, N (R 9 ) SOR 7 -, -N (R 9 ) SO 2 R 7 -, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl
  • R 4 and R 5 are independently selected at each occurrence from hydrogen, halogen, OH, NH 2 , CN, NO 2 , optionally substituted C 1-4 alkyl, optionally substituted C 1 -C 4 heteroalkyl, optionally substituted C 1- 4 alkoxy, optionally substituted C 1-4 heteroalkyl, optionally substituted C 1-4 haloalkyl, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , -NH- (optionally substituted C 3-10 carbocyclyl) , and optionally substituted 3-to 10-membered heterocyclyl;
  • R 6 is selected from hydrogen, halogen, CN, NO 2 , optionally substituted C 1-6 alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted C 3-10 carbocyclyl, and optionally substituted 3-to 10-membered heterocyclyl;
  • R 7 is selected from null, optionally substituted C 1-8 alkylene, optionally substituted C 1 -C 8 heteroalkylene, optionally substituted C 2 -C 8 alkenylene, optionally substituted C 2 -C 8 alkynylene, optionally substituted C 1-8 heteroalkylene, optionally substituted C 1-8 alkoxy, optionally substituted C 3-10 carbocyclyl, -O- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 1-8 alkylamino, -NH- (optionally substituted C 3-10 carbocyclyl) , optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl;
  • R 8 and R 9 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1-8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 3- 10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 7 and R 8 together with the atom to which they are connected, optionally form an optionally substituted C 3-10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 10 , R 11 , and R 12 are independently selected from hydrogen, optionally substituted C 1-8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 2-8 alkenyl, optionally substituted C 2- 8 alkynyl, optionally substituted C 3-10 carbocyclyl, optionally substituted 3-to 10-membered heterocyclyl, optionally substituted C 6-10 aryl, and optionally substituted 5-to 10-membered heteroaryl; or
  • R 11 and R 12 are together with the atom to which they are connected to form an optionally substituted C 3 -C 10 carbocyclyl or an optionally substituted 3-to 10-membered heterocyclyl;
  • R 13 and R 14 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 1 -C 8 alkoxy-C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl, optionally substituted C 1 -C 8 hydroxyalkyl, optionally substituted C 1 -C 8 aminoalkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted 3-10 membered carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or
  • R’ and R together with the atom to which they are connected optionally form a 3-20 membered carbocyclyl or 3-20 membered heterocyclyl ring;
  • n 0, 1, 2, 3, or 4.
  • L is selected from
  • Y 1 is N
  • Y 2 is N
  • Y 3 is C
  • Y 4 is C
  • Ar 1 is C 6-10 aryl optionally substituted with halogen. In some embodiments, Ar 1 is
  • Ar 2 is C 6-10 aryl optionally substituted with NR 11 R 12 . In some embodiments, Ar 2 is
  • R 3 is optionally substituted 3-to 10-membered heterocyclyl. In some embodiments, R 3 is
  • R 4 is hydrogen
  • Z is C (R 5 ) 2 . In some embodiments, Z is CH 2 .
  • n 0.
  • X 1 is CR 1 , X 2 is CH, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is CR 1 .
  • X 1 is CR 1 , X 2 is N, and X 3 is NR 1 .
  • X 1 is NR 1 , X 2 is N, and X 3 is CR 1 .
  • X 1 is NR 1 , X 2 is CH, and X 3 is N.
  • X 1 is N, X 2 is CH, and X 3 is NR 1 .
  • R 1 is methyl. In some embodiments, R 1 is
  • the TRK ligand comprises a moiety of Formula 1;
  • R 1 , R 2 , R 3 , R 4 , Ar, and X are defined as before.
  • the TRK ligand comprises a moiety of Formula 1
  • X is selected from CR’R”, CO, O, S, SO, SO 2 , and NR’, wherein
  • R’ and R are independently selected from hydrogen, halogen, OH, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1-8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylamino, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, and optionally substituted 3-10 membered heterocyclyl; or
  • R’ and R” together with the atom to which they are connected optionally form an optionally substituted 3-8 membered carbocyclyl or heterocyclyl ring;
  • R is selected from optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;
  • R 1 , R 2 , and R 3 are independently selected from hydrogen, halogen, CN, NO 2 , OR 5 , SR 6 , NR 7 R 8 , COR 5 , CO 2 R 5 , C (O) NR 7 R 8 , SOR 5 , SO 2 R 5 , SO 2 NR 7 R 8 , NR 7 C (O) R 8 , NR 5 C (O) NR 7 R 8 , NR 7 SOR 8 , NR 7 SO 2 R 8 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted C 3 -C 10 cycloalkoxy, optionally
  • R 5 , R 6 , R 7 , and R 8 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 10 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, or optionally substituted heteroaryl, or
  • R 7 and R 8 together with the atom to which they are connected optionally form an optionally substituted 3-8 membered heterocyclyl ring;
  • R 4 is connected to the linker moiety of the bivalent compound, and is selected from a bond, OR 9 , SR 9 , NR 10 R 11 , COR 9 , CO 2 R 9 , CONR 10 R 11 , SOR 9 , SO 2 R 9 , SO 2 NR 10 R 11 , NR 10 COR 11 , NR 9 CONR 10 R 11 , NR 10 SOR 11 , NR 10 SO 2 R 11 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substitute
  • R 9 , R 10 , and R 11 are independently selected from null, a bond, hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 10 and R 11 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring;
  • Ar is selected from aryl and heteroaryl group, each of which is optionally substituted with one or more substituents independently selected from hydrogen, halogen, CN, NO 2 , OR 12 , SR 12 , NR 13 R 14 , COR 12 , CO 2 R 12 , CONR 13 R 14 , SOR 12 , SO 2 R 12 , SO 2 NR 13 R 14 , NR 13 COR 14 , NR 15 C (O) NR 13 R 14 , NR 13 SOR 14 , NR 13 SO 2 R 14 , optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8
  • R 12 , R 13 , R 14 , and R 15 are independently selected from hydrogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 heteroalkyl, optionally substituted C 1 -C 8 alkoxy, optionally substituted C 1 -C 8 alkoxyC 1 -C 8 alkyl, optionally substituted C 1 -C 8 alkylaminoC 1 -C 8 alkyl, optionally substituted C 3 -C 8 carbocyclyl, optionally substituted C 3 -C 8 cycloalkoxy, optionally substituted 3-8 membered heterocyclyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted aryl, and optionally substituted heteroaryl, or
  • R 13 and R 14 together with the atom to which they are connected optionally form a 3-8 membered carbocyclyl or heterocyclyl ring.
  • X is selected from CR’R”, O, and NR’, wherein
  • R’ and R” are independently selected from hydrogen, F, OH, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 heteroalkyl, and optionally substituted C 1 -C 3 alkoxy, or
  • R’ and R” together with the atom to which they are connected form an optionally substituted 3-6 membered carbocyclyl or heterocyclyl ring.
  • X is selected from CH 2 , cyclopropylene, CHF, CF 2 , O, NH, NCH 3 , NCH 2 CH 3 , and N-isopropyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/CN2021/078240 2020-02-26 2021-02-26 Tropomyosin receptor kinase (trk) degradation compounds and methods of use Ceased WO2021170109A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2022010465A MX2022010465A (es) 2020-02-26 2021-02-26 Compuestos de degradacion del receptor cinasa relacionado con trompomiosina y metodos de uso.
AU2021225981A AU2021225981A1 (en) 2020-02-26 2021-02-26 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US17/904,822 US12410171B2 (en) 2020-02-26 2021-02-26 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP21760113.7A EP4110772A4 (en) 2020-02-26 2021-02-26 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
CN202510191023.3A CN120058711A (zh) 2020-02-26 2021-02-26 原肌球蛋白受体激酶(trk)降解化合物和使用方法
CN202180031506.7A CN115697989B (zh) 2020-02-26 2021-02-26 原肌球蛋白受体激酶(trk)降解化合物和使用方法
JP2022551553A JP7692924B2 (ja) 2020-02-26 2021-02-26 トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
IL295799A IL295799A (en) 2020-02-26 2021-02-26 Trophomyosin receptor kinase (trk) degradation compounds and methods of use
CA3173262A CA3173262A1 (en) 2020-02-26 2021-02-26 Tropomyosin receptor kinase (trk) degradation compounds and methods of use
KR1020227033274A KR20230010070A (ko) 2020-02-26 2021-02-26 트로포미오신 수용체 키나제(trk) 분해 화합물 및 사용 방법
BR112022016901A BR112022016901A2 (pt) 2020-02-26 2021-02-26 Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020076748 2020-02-26
CNPCT/CN2020/076748 2020-02-26

Publications (1)

Publication Number Publication Date
WO2021170109A1 true WO2021170109A1 (en) 2021-09-02

Family

ID=77490737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/078240 Ceased WO2021170109A1 (en) 2020-02-26 2021-02-26 Tropomyosin receptor kinase (trk) degradation compounds and methods of use

Country Status (11)

Country Link
US (1) US12410171B2 (https=)
EP (1) EP4110772A4 (https=)
JP (1) JP7692924B2 (https=)
KR (1) KR20230010070A (https=)
CN (2) CN120058711A (https=)
AU (1) AU2021225981A1 (https=)
BR (1) BR112022016901A2 (https=)
CA (1) CA3173262A1 (https=)
IL (1) IL295799A (https=)
MX (1) MX2022010465A (https=)
WO (1) WO2021170109A1 (https=)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161414A1 (zh) * 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
WO2022268066A1 (zh) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2023036175A1 (zh) * 2021-09-08 2023-03-16 南京明德新药研发有限公司 戊二酰亚胺类化合物与其应用
WO2023055952A1 (en) * 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds
WO2023066350A1 (zh) * 2021-10-22 2023-04-27 标新生物医药科技(上海)有限公司 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
WO2023086564A1 (en) * 2021-11-12 2023-05-19 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CN116217578A (zh) * 2021-12-30 2023-06-06 清华大学 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
WO2023131167A1 (zh) * 2022-01-04 2023-07-13 海思科医药集团股份有限公司 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
WO2023193760A1 (en) * 2022-04-06 2023-10-12 Cullgen (Shanghai) , Inc. Compounds and methods of treating cancers
WO2023245150A1 (en) * 2022-06-16 2023-12-21 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
WO2024027792A1 (en) * 2022-08-05 2024-02-08 Shenzhen Newdel Biotech Co., Ltd. Protein kinase degrading agent, medicament and use
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2024149362A1 (en) * 2023-01-13 2024-07-18 Shenzhen Newdel Biotech Co., Ltd. Use of compound 1 in treatment or prevention of atopic dermatitis
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
JP2025502928A (ja) * 2021-12-08 2025-01-30 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｅ３ユビキチンリガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
WO2025061203A1 (zh) * 2023-09-21 2025-03-27 成都茵创园医药科技有限公司 Irak降解剂及其用途
WO2025070690A1 (ja) 2023-09-29 2025-04-03 第一三共株式会社 ３－フェニルプロピルアミン誘導体
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. Proteolysis regulator and method for using same
JP7814386B2 (ja) * 2020-11-05 2026-02-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
CN116589445B (zh) * 2022-02-14 2026-02-27 标新生物医药科技(上海)有限公司 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用
WO2025155827A1 (en) * 2024-01-18 2025-07-24 St. Jude Children's Research Hospital, Inc. Small-molecule modulators of lymphocyte-specific protein tyrosine kinase and casein kinase 1a
CN119613482A (zh) * 2024-12-09 2025-03-14 中国药科大学 具有端氨基结构的化合物及其制备方法、药物组合物和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096709A1 (en) * 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
CN106458993A (zh) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
CN108601764A (zh) * 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109912655A (zh) * 2017-12-13 2019-06-21 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
WO2020038415A1 (en) * 2018-08-22 2020-02-27 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
CN103153335A (zh) 2010-06-30 2013-06-12 布兰代斯大学 小分子靶定的蛋白质降解
WO2012037155A2 (en) 2010-09-13 2012-03-22 Gtx, Inc. Tyrosine kinase inhibitors
CA2823837A1 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2013170147A1 (en) 2012-05-11 2013-11-14 Yale University Compounds useful for promoting protein degradation and methods using same
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP3097091A1 (en) 2014-01-24 2016-11-30 AbbVie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
KR20180132861A (ko) 2016-04-12 2018-12-12 더 리젠츠 오브 더 유니버시티 오브 미시간 Bet 단백질 분해제
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR101825065B1 (ko) 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
GB201610156D0 (en) 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
WO2017223452A1 (en) 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CN106543185B (zh) 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
US10040804B2 (en) 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CN110573507B (zh) 2017-04-14 2023-11-14 邓迪大学 小分子
CN108976278B (zh) 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
WO2018226542A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
EP3826675A1 (en) 2018-07-24 2021-06-02 January Therapeutics, Inc. Nanoparticle compositions
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
WO2023055952A1 (en) 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458993A (zh) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
WO2016096709A1 (en) * 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
CN108601764A (zh) * 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109912655A (zh) * 2017-12-13 2019-06-21 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
WO2020038415A1 (en) * 2018-08-22 2020-02-27 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERGE S.M ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19
See also references of EP4110772A4

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2022161414A1 (zh) * 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
WO2022268066A1 (zh) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2023036175A1 (zh) * 2021-09-08 2023-03-16 南京明德新药研发有限公司 戊二酰亚胺类化合物与其应用
WO2023055952A1 (en) * 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds
WO2023066350A1 (zh) * 2021-10-22 2023-04-27 标新生物医药科技(上海)有限公司 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
US12291528B2 (en) 2021-11-12 2025-05-06 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
US11814383B2 (en) 2021-11-12 2023-11-14 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
WO2023086564A1 (en) * 2021-11-12 2023-05-19 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
JP2025502928A (ja) * 2021-12-08 2025-01-30 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｅ３ユビキチンリガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
CN116217578A (zh) * 2021-12-30 2023-06-06 清华大学 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物
CN116217578B (zh) * 2021-12-30 2026-02-24 清华大学 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物
WO2023131167A1 (zh) * 2022-01-04 2023-07-13 海思科医药集团股份有限公司 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
WO2023193760A1 (en) * 2022-04-06 2023-10-12 Cullgen (Shanghai) , Inc. Compounds and methods of treating cancers
EP4504716A4 (en) * 2022-04-06 2026-03-11 Cullgen Shanghai Inc CANCER COMPOUNDS AND TREATMENT METHODS
WO2023245150A1 (en) * 2022-06-16 2023-12-21 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
WO2024027792A1 (en) * 2022-08-05 2024-02-08 Shenzhen Newdel Biotech Co., Ltd. Protein kinase degrading agent, medicament and use
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2024149362A1 (en) * 2023-01-13 2024-07-18 Shenzhen Newdel Biotech Co., Ltd. Use of compound 1 in treatment or prevention of atopic dermatitis
WO2025061203A1 (zh) * 2023-09-21 2025-03-27 成都茵创园医药科技有限公司 Irak降解剂及其用途
WO2025070690A1 (ja) 2023-09-29 2025-04-03 第一三共株式会社 ３－フェニルプロピルアミン誘導体
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Also Published As

Publication number Publication date
US12410171B2 (en) 2025-09-09
CA3173262A1 (en) 2021-09-02
EP4110772A4 (en) 2024-04-03
US20230257380A1 (en) 2023-08-17
CN115697989B (zh) 2025-03-18
JP2023514872A (ja) 2023-04-11
CN115697989A (zh) 2023-02-03
AU2021225981A1 (en) 2022-09-29
JP7692924B2 (ja) 2025-06-16
EP4110772A1 (en) 2023-01-04
MX2022010465A (es) 2022-12-13
CN120058711A (zh) 2025-05-30
IL295799A (en) 2022-10-01
KR20230010070A (ko) 2023-01-17
BR112022016901A2 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
WO2021170109A1 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
WO2020038415A1 (en) Tropomyosin receptor kinase (trk) degradation compounds and methods of use
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
US11969472B2 (en) Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
KR20250008772A (ko) 테트라하이드로이소퀴놀린 헤테로이작용성 bcl-xl 분해제
AU2023265886A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CN120225525A (zh) 用于调节her2的化合物及方法
JP2026508123A (ja) Ｉｋｚｆ２を分解するインドール化合物及びその用途
KR20240120681A (ko) Ikzf2를 분해하는 인돌 화합물 및 이의 용도
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21760113

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022551553

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3173262

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022016901

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202217052464

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021225981

Country of ref document: AU

Date of ref document: 20210226

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021760113

Country of ref document: EP

Effective date: 20220926

ENP Entry into the national phase

Ref document number: 112022016901

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220824

WWG Wipo information: grant in national office

Ref document number: 202180031506.7

Country of ref document: CN

WWG Wipo information: grant in national office

Ref document number: 17904822

Country of ref document: US